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ABSTRACT
The pituitary gland is a critical organ that is necessary for many physiological
processes, including growth, reproduction, and stress response. These vital processes
are regulated through the secretion of pituitary hormones from specialized cell types.
Pituitary hormone-producing cells arise from a common pool of pituitary progenitors in
the developing Rathke’s pouch, and mutations that disrupt the formation and
differentiation of pituitary progenitors often result in hypopituitarism, pituitary
adenomas, or craniopharyngiomas. Thus, it is necessary to determine the mechanisms
of pituitary development in order to understand the ways in which these congenital
defects and tumors develop and disrupt pituitary function. Canonical WNT signaling
through CTNNB1 (β-CATENIN) is known to regulate the formation of the POU1F1
lineage, which includes somatotropes, lactotropes, and thyrotropes. When β-catenin is
deleted during the initial formation of pituitary progenitors, Pou1f1 is not transcribed,
leading to the loss of the POU1F1 lineage. However, when β-catenin is deleted after
lineage specification, there is no observable effect. Similarly, the generation of a βcatenin gain-of-function allele in early pituitary progenitors or stem cells results in the
formation of craniopharyngiomas, while stimulating β-CATENIN in differentiated cell
types has no effect. To date, previous studies have not determined the role of canonical
WNT signaling in-between these two critical time points in pituitary organogenesis.
PROP1 is a pituitary-specific transcription factor that is expressed starting at e10.5, after
v

pituitary progenitor formation, and the peak of its expression occurs around e12.5, prior
to lineage specification. We utilized the Prop1-cre to conduct both loss- and gain-offunction studies on β-CATENIN during this critical window in pituitary gland
development. Our results demonstrate that pituitary progenitors remain sensitive to βCATENIN at this time point. Deletion of β-catenin during this critical window resulted in
loss of the POU1F1 lineage, as expected, as well as an increase in the expression of
TBX19 (TPIT), with a subsequent increase in the corticotrope population. Stimulating βCATENIN during this same time point resulted in the formation of nodules resembling
those in adamantinomatous craniopharyngiomas (ACPs), along with complete disruption
of cell cycle exit and pituitary lineage determination, loss of all hormone-secreting cell
types, and a reversion to a more oral ectoderm-like state.
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CHAPTER 1
INTRODUCTION
The endocrine system is a collection of glands, all of which have functions in vital
physiological processes, such as growth and development, stress management,
reproduction, and metabolism. The pituitary gland is often called the master gland
because of its role in regulating the functions of the other endocrine glands through the
secretion of hormones from specialized hormone cell types. In humans, the pituitary
gland is composed of two distinct lobes: the anterior lobe, also known as the
adenohypophysis, and the posterior lobe, or neurohypophysis. The anterior lobe
originates from an invagination of the oral ectoderm, under the direction of BMP and
FGF signaling from the neural ectoderm of the ventral diencephalon (1).
This preliminary pituitary gland, called Rathke’s pouch, is composed of pituitary
progenitor cells, which then undergo cell specification and differentiation in
coordination with cell cycle exit and intrinsic signaling factors. From this common pool
of pituitary progenitors, cells begin to differentiate through one of three distinct cell
specification pathways. The POU1F1 lineage is composed of somatotropes, which
secrete growth hormone (GH); thyrotropes, which secrete thyroid-stimulating hormone
(TSH); and lactotropes, which secrete prolactin (PRL) (2). Cells that express TBX19 (TPIT)
differentiate into one of the two POMC-derived cell types: corticotropes, which secrete
adrenocorticotropic hormone (ACTH) and melanotropes, which secrete melanocyte1

stimulating hormone (MSH) (3). The gonadotropes, which secrete follicle-stimulating
hormone (FSH) and luteinizing hormone (LH), express NR5A1 (SF1) and αGSU (4).
To date, research on pituitary cell specification and differentiation has yielded a
transcription factor hierarchy that originates with PITX1 and LHX3 marking potential
pituitary progenitors within the oral ectoderm at e8.5 (5,6). Rathke’s pouch, under
direction from the ventral diencephalon, begins to invaginate from the oral ectoderm at
e9.5, and at this time, pituitary progenitors begin to express HESX1 (7). By e11.5,
Rathke’s pouch is completely closed off from the oral ectoderm and the proliferating
progenitors around its lumen express PROP1 (8,9). From this pool of PROP1-positive
progenitors, we generate all hormone-producing cell types, along with a population of
pituitary stem cells, which can be activated to undergo differentiation later in life as
needed, such as during puberty or times of prolonged stress (10).
A greater understanding of pituitary gland development will help us to
determine how mutations develop and disrupt pituitary function. Mutations during
pituitary development most often result in hypopituitarism, pituitary adenomas, or
craniopharyngiomas. Combined pituitary hormone deficiency (CPHD) is a common form
of hypopituitarism that involves impaired production of growth hormone and one or
more other pituitary hormones (11). Pituitary adenomas arise from mutations in specific
hormone-producing cell types, leading to an excess secretion of that particular
hormone. Acromegaly is a prime example of a pituitary adenoma wherein an excess of
growth hormone is secreted, leading to bone overgrowth, significant morbidity, and
increased mortality (12). Adamantinomatous craniopharyngiomas (ACPs) are unique in
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that they arise from pituitary progenitors or stem cells and are not associated with an
excess secretion of pituitary hormones (13). Rather, these benign tumors are slowgrowing and locally invasive, resulting in high morbidity from the shear mass effects of
the tumor. Because of their infiltrative behavior and intracranial location, these tumors
are difficult to eradicate and often recur after surgical resection (14).
Many instances of hypopituitarism or pituitary tumor formation have been
linked to mutations in key transcription factors. Mutations in PROP1 or POU1F1 are the
two most common causes of CPHD, leading to a loss of the POU1F1 lineage (11).
Canonical WNT signaling through β-CATENIN is known to regulate the formation of the
POU1F1 lineage, as deletion of β-catenin in early pituitary progenitors results in a failure
to transcribe Pou1f1 (15). Canonical WNT signaling has also been linked to the formation
of craniopharyngiomas, as stimulating β-CATENIN early in pituitary development results
in an ACP-like pituitary phenotype (16). It is interesting to note, however, that altering
β-CATENIN expression after cell specification has occurred does not result in any
observable pituitary defects (15,16). Previous studies have not yet determined if βCATENIN plays a role in pituitary development in-between these two critical timepoints:
after pituitary progenitor formation, but before cell specification. Here, we utilize the
Prop1-cre to conduct both loss and gain-of-function studies on β-CATENIN during this
critical window in pituitary gland development.
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CHAPTER 2
LITERATURE REVIEW
Pituitary gland organogenesis is a complex process involving coordination
between both intrinsic and extrinsic signals. Previous studies in mice have shown that
the pituitary gland is derived from two ectodermal regions in close proximity to each
other: the neural ectoderm of the ventral diencephalon and the surface ectoderm of the
oral epithelium (5). The ventral diencephalon evaginates to form an infundibulum,
which gives rise to the posterior lobe of the adult pituitary. The anterior lobe, on the
other hand, is derived from an invagination of the oral ectoderm, called Rathke’s pouch.
In mice, Rathke’s pouch also forms an intermediate lobe, which houses the
melanotropes in the adult pituitary gland (3). These two ectodermal structures are vital
not only for the initial formation of the preliminary pituitary, but also for the extrinsic
signals that regulate the size and shape of the forming pituitary gland. BMP and FGF
signaling factors in the ventral diencephalon are called the pituitary organizer, in
reference to their role in regulating pituitary gland induction and growth (17).
Bone morphogenic protein 4 (BMP4) is expressed in the infundibular region of
the ventral diencephalon and is responsible for initiating the invagination of Rathke’s
pouch from the oral ectoderm, as indicated by the failure of Bmp4-/- mice to form a
viable Rathke’s pouch at e9.5 (18). Fibroblast growth factors 8 (FGF8) and 10 (FGF10)
are expressed in an overlapping expression pattern with BMP4 and are responsible for
4

promoting proliferation in the forming Rathke’s pouch (1,19). Sonic hedgehog (SHH)
expression is located rostral and ventral to the regions of BMP and FGF expression in the
ventral diencephalon and acts in opposition to these signaling factors, resulting in
restricted pituitary gland growth (5). Canonical WNT signaling in the ventral
diencephalon acts to regulate the correct patterning of the other signaling factors in the
pituitary organizer. Conditional deletion of β-catenin in the ventral diencephalon results
in a hypoplastic pituitary gland, resulting from a smaller region of FGF expression in the
pituitary organizer (17). Other WNT factors, including TCF4 and WNT5A, are known to
restrict the expansion of BMPs and FGFs in the ventral diencephalon, as deletion of
either of these factors results in a hyperplastic pituitary gland due to an expanded
pituitary organizer (20,21). Other signaling factors like Noggin, a known BMP inhibitor,
also affect the correct patterning of the pituitary organizer, as indicated by the fact that
Noggin-/- embryos have expanded BMP4 activity in the ventral diencephalon, leading to
the recruitment of additional oral ectoderm into the forming Rathke’s pouch (22).
SHH, in addition to its role in the pituitary organizer, is also expressed in the oral
ectoderm, but is completely excluded from the invaginating Rathke’s pouch, creating a
defined SHH barrier between the oral epithelium and the preliminary pituitary [Fig. 2.1]
(23). Other oral ectoderm transcription factors, including PITX1 and PITX2, are
important for early pituitary gland development. PITX1/2 are expressed in all oral
ectoderm at e8.5, including the SHH-negative region of developing Rathke’s pouch [Fig.
2.1] (23). These two transcription factors are required for Rathke’s pouch proliferation,
as indicated by severe pituitary hypoplasia in Pitx1-/-; Pitx2-/- embryos (24). Loss of PITX1
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and PITX2 also leads to a failure to express LHX3, another early pituitary marker [Fig.
2.1] (24). Lhx3-/- embryos are lacking the anterior and intermediate lobes of the
pituitary, a direct effect of its role in the proliferation of cells in Rathke’s pouch (6,25).
HESX1, a transcription factor primarily involved in anterior forebrain development,
begins to be expressed in Rathke’s pouch at e9.5, and is essential for pituitary
progenitor formation, as mutations in HESX1 can cause CPHD in association with septo
optic dysplasia [Fig. 2.1] (7,26).
PROP1 is the first pituitary-specific transcription factor expressed during pituitary
gland development. Its expression begins at e10.5, corresponding with a downregulation of HESX1 in pituitary progenitors (5,8). PROP1 is expressed in all pituitary
progenitors at e11.5, as these proliferating cells begin to exit the cell cycle [Fig. 2.1]
(9,27). Early pituitary progenitors in Rathke’s pouch express markers of proliferation and
growth, including Ki67, SOX2, CCND1, and CCND2, as well as markers of an epithelial
tissue state, such as E-CADHERIN (28,29). Upon cell cycle exit, pituitary progenitors
begin to undergo an epithelial-to-mesenchymal (EMT)-like transition. Because the
anterior lobe parenchyma is not a true mesenchyme, we will refer to this transition as
an epithelial-to-parenchymal transition, or EPT. During EPT, these post-mitotic pituitary
progenitors migrate from the lumen of Rathke’s pouch to the developing anterior lobe
and express transitional markers, including p57Kip2, SOX2, and SOX9 (28,29). PROP1 is
essential for progression through EPT and directly regulates the expression of factors
required for EPT, including ZEB2, GLI2, MMP2, MMP3, and MMP16 (30,31).
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Starting around e13.5, this PROP1-positive population of cells begins to
differentiate into the hormone-producing cell types of the anterior pituitary. PROP1, in
conjunction with β-CATENIN, is directly responsible for the transcription of POU1F1,
through suppression of HESX1 expression and binding to the POU1F1 promoter to
activate transcription [Fig. 2.1] (15,32). Prop1df/df mice, also referred to as Ames dwarf
mice, have severely reduced numbers of somatotropes, lactotropes, and thyrotropes,
consistent with a significant decrease in cells expressing POU1F1 (31,33). In human
patients with PROP1 mutations, anterior pituitary function deteriorates progressively,
and includes adrenal insufficiency in addition to deficiencies in GH, TSH, and the
gonadotropins (34). As expected, Pou1f1dw/dw mice, or Snell dwarf mice, have
hypoplastic anterior pituitaries in combination with deficiencies in all POU1F1 lineage
cell types (2). β-CATENIN, despite its role in activating Pou1f1 transcription, is not
involved in maintaining POU1F1 expression. Conditionally deleting β-catenin after initial
POU1F1 transcription, using a Pou1f1-cre, did not affect POU1F1 expression, or that of
its three lineage cell types (15).
Proopiomelanocortin (POMC) begins to be expressed around e13.5 in Rathke’s
pouch and marks developing corticotropes and melanotropes (35). TBX19 and PITX1 act
as co-activators of POMC gene transcription, and human mutations in Tbx19 result in
isolated ACTH deficiency [Fig. 2.1] (3,35). NEUROD1 is also important for the
development of the POMC-derived cell types, but is more specifically involved in
corticotrope development (36). ACTH-positive corticotropes are normally expressed as
early as e13.5 in wild-type embryos; however, in Neurod1-/- embryos, corticotrope
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differentiation is delayed (36). This delay is transient and ACTH expression recovers
completely by e16.5, suggesting that NEUROD1 is required for the correct timing of
corticotrope differentiation (36). TBX19 is also important for repressing the expression
of other lineage-specific transcription factors, such as POU1F1 and SF1, as seen in
Tbx19-/- embryos, which generate gonadotropes and thyrotropes in the developing
intermediate lobe instead of the usual melanotropes (35). HES1, a downstream effector
of NOTCH signaling, is similarly involved in regulating the different cell specification
pathways, as Hes1-/- embryos contain somatotropes instead of melanotropes in the
intermediate lobe (37). This suggests a possible antagonistic relationship between the
three cell specification pathways, to regulate formation versus repression of the
different hormone-producing cell types.
Potential gonadotropes begin to express steroidogenic factor 1 (SF1) at e13.5, an
orphan nuclear receptor involved in multiple levels of the reproductive axis [Fig. 2.1]
(38). Outside of the pituitary gland, SF1 regulates the enzymes that produce sex steroids
in the adrenal glands, testes, and ovaries (4). Within anterior pituitary gonadotropes,
SF1 directly regulates the expression of LHβ, FSHβ, and αGSU, the alpha-subunit partner
of the heterodimeric glycoprotein hormones TSH, LH, and FSH (38,39). SF1 is also
responsible for regulating the expression of the GNRH receptor, which receives signals
from gonadotropin-releasing hormone neurons in the hypothalamus (38). Sf1-/- embryos
are severely affected by the loss of this key regulator of the hypogonadal axis and are
lacking adrenal glands, reproductive organs, and have female internal genitalia in
addition to deficiencies in LHβ, FSHβ, GNRHR, and αGSU (4,38).
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Cell specification and differentiation continue through e18.5 in mice, with most
anterior pituitary hormones detectable prior to birth [Fig. 2.1]. The one exception is
prolactin, which is not detectable via immunostaining in lactotropes until after birth
(40). These fully differentiated hormone-producing cells of the anterior lobe now
express markers of anterior pituitary parenchyma, including p27Kip1 and N-CADHERIN
(28,29,41). As they differentiate, cells within the anterior lobe begin to sort themselves
into cell-specific networks that are highly structured and extensive (42). This network of
cells in close proximity to each other and to the invading vasculature allows for a more
robust and coordinated response of these cells to hormone-releasing signals from the
hypothalamus (42). As previously mentioned, melanotropes do not migrate into the
anterior lobe in mice, but instead remain in the intermediate lobe that is formed from
the dorsal region of Rathke’s pouch that sits along the lumen (3).
Directly opposite of the intermediate lobe, along the ventral side of the lumen,
rests a niche of pituitary stem cells (10). These cells arise from the same population of
PROP1-positive, SOX2-positive pituitary progenitors as the rest of the cells in the
anterior and intermediate lobes; however, they become quiescent and do not undergo
an EPT (29). These quiescent cells express common markers of stem cells, including
SOX2, SOX9, OCT4, and E-CADHERIN, along with other transcription factors and
receptors, such as PROP1 and GFRα2 (10,29). Pituitary stem cells are able to undergo
differentiation later in life, particularly when the demand for a specific hormone is
greater than the anterior pituitary can manage (43). Two prime examples of this are
during pregnancy and lactation, when the demand for prolactin is high, and during
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periods of prolonged stress, when more corticotropes must be generated to meet the
increased need for ACTH (44).
Many pituitary disorders and tumors arise during embryogenesis, as a result of
mutations in key regulators of pituitary gland development. Hypopituitarism as a whole
is a fairly rare disorder, with an estimated 148,000 people suffering from some form of
hypopituitarism in the United States (45). Combined pituitary hormone deficiency, or
CPHD, is a form of hypopituitarism that is characterized by a deficiency in growth
hormone in conjunction with deficiencies in one or more other pituitary hormones (11).
The two most common causes of CPHD are mutations in PROP1 or POU1F1, leading to
deficiencies in the POU1F1 lineage cell types (11). Other transcription factors that have
been linked to pituitary hormone deficiencies include HESX1, LHX3, LHX4, PITX1, PITX2,
OTX2, SOX2, SOX3, SF1, and TBX19 (26,35,38,46,47). Despite the fact that so many
members of the transcription factor hierarchy are included in this list, less than half of
all known causes of congenital hypopituitarism have been attributed to one of these
transcription factors (46). Currently, the only available treatment for hypopituitarism is
hormonal replacement therapy, which is not ideal because medications cannot mimic
the pulsatile hormone secretions of a normal pituitary gland (34,48,49). In addition to
complex endocrine disruptions, patients with hypopituitarism have also been shown to
have increased mortality, although the exact mechanisms involved are largely unknown
(50).
Craniopharyngiomas are intracranial tumors that arise from mutations in the
pituitary stem cell population (51). There are two subtypes of craniopharyngiomas:

10

papillary (PCP) and adamantinomatous (ACP); of these, ACPs are the most common,
accounting for up to 10% of pediatric intracranial tumors (51,52). ACPs are characterized
histologically by collections of whorl-like nodules consisting of cytokeratin-enriched
abnormal epithelium (51). These epithelial-like cell clusters most closely resemble the
nodules of other epithelial stem cell derived tumors, including basal cell carcinomas,
pilomatricomas, etc (53,54). Although craniopharyngiomas are histologically benign,
they can still be devastating because of their highly infiltrative behavior, subsequent
endocrine disruptions, and tendency to recur after surgical resection (55). Current ACP
therapies are limited to surgery and radiotherapy, which have limited success due to the
delicate nature of the intracranial region in which craniopharyngiomas grow and invade
the surrounding tissues (56). A better understanding of the molecular pathways
involved in ACP development may help us identify novel therapeutic targets. Canonical
WNT signaling through β-CATENIN has been identified as a major player in ACP
formation, as approximately 95% of ACP tumors contain activating mutations in βcatenin (51,52).
There are multiple WNT signaling transduction pathways, categorized as either
canonical or non-canonical, based on whether the signal is mediated by the canonical
WNT factor, β-CATENIN (57). Both canonical and non-canonical WNT pathways involve
the binding of an extracellular WNT ligand to a Frizzled (FZD) receptor in the cell’s
membrane (57). The FZD receptor can utilize multiple co-receptors, such as LRP5/6 and
ROR1/2, to bind different WNT ligands depending on which co-receptor is used (58). The
combination of ligand, receptor, and co-receptor then determines whether a canonical
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or non-canonical signaling pathway is activated (59–61). In the absence of a WNT ligand,
β-CATENIN expression is regulated by a complex containing APC, GSK3β, and AXIN (57).
This complex binds and ubiquitinates β-CATENIN in the cytoplasm, targeting it for
degradation by proteasomes (57). However, when a WNT ligand binds to its FZD
receptor and activates a canonical signaling cascade, the APC/GSK3β/AXIN complex is
inhibited, allowing β-CATENIN to accumulate in the cytoplasm, enter the nucleus, and
regulate transcription of various target genes (57). β-CATENIN is most commonly a coactivator or co-repressor of transcription in conjunction with another transcription
factor, primarily those of the TCF/LEF family (62). In addition to being a mediator of
canonical WNT signaling through its interactions with β-CATENIN, LEF1 is also a target of
canonical WNT signaling in a β-CATENIN-dependent, LEF-independent manner (62).
TCF/LEF factors are considered to be the ubiquitous transcription-regulating partners of
β-CATENIN; however, β-CATENIN can also interact with other tissue-specific
transcription factors (57). A prime example of this is PROP1, which, as we have already
discussed, acts in conjunction with β-CATENIN to activate POU1F1 transcription (15).
Another relevant example is the ability of β-CATENIN to convert PITX2 from a repressor
to an activator in order to regulate cell proliferation (63). PITX2 is required for CCND2,
CCND1, and c-MYC expression, all of which are G1 cell cycle control genes; therefore,
through its interaction with PITX2, β-CATENIN is able to regulate the expression of these
three genes (64).
Canonical WNT signaling is important for many different aspects of embryonic
development, including progenitor formation, cell specification and differentiation,

12

stem cell regulation, and EMT (65,66). Previous studies have identified many WNT
signaling factors within Rathke’s pouch and have begun to determine the roles they play
in pituitary gland development (67). To date, canonical WNT signaling has been shown
to regulate the patterning of the pituitary organizer, progenitor formation and
proliferation, and POU1F1 transcription (15,17,21,41,64). However, there is one limiting
factor to studying the role of β-CATENIN in pituitary development. Because β-catenin-/embryos are embryonic lethal at e8.5, prior to the induction of Rathke’s pouch, we must
use Cre-Lox recombination techniques to target deletion or stimulation of β-catenin only
in the pituitary gland (68). Experiments using the Hesx1-cre or Pitx1-cre are ideal for
determining the effect of β-CATENIN on early pituitary progenitors, while the Pou1f1cre, Sf1-cre, Gh-cre, etc, are better for experiments on the role of β-CATENIN after cell
specification has occurred (7,15,16,69).
Using the Pitx1-cre, previous studies have shown that conditional deletion of βcatenin in early pituitary progenitors results in the loss of the POU1F1 lineage (15).
However, deleting β-catenin after cell specification, using the Pou1f1-cre, does not
result in any observable pituitary defect (15). Other experiments have sought to
determine the effect of stimulating canonical WNT signaling on pituitary gland
development. Conditional deletion of β-CATENIN exon 3 results in an activated form of
β-CATENIN which cannot be ubiquitinated and degraded, even in the absence of a WNT
ligand (70). Using this gain-of-function (GOF) allele in combination with either the
Hesx1-cre or the Sox2-cre, it was determined that stimulating β-CATENIN in early
pituitary progenitors results in an ACP-like nuclear accumulation of β-CATENIN,
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formation of whorled clusters of β-CATENIN-positive cells, and an overall hyperplastic
pituitary gland (16). Similar to the conditional deletion experiments, there is no effect
on the pituitary gland when stimulating β-CATENIN after cell specification has occurred,
using a Pou1f1-cre, Gh-cre, or Prl-cre (16).
To date, no experiments have been conducted to determine the role of βCATENIN in-between these two major time points: after pituitary progenitor formation
but prior to cell specification. None of the aforementioned cre recombinases are
expressed in the correct temporal and spatial location to allow us to conduct these
experiments. Thus, we will use the recently developed Prop1-cre to determine the effect
of deleting β-CATENIN in-between these two key time points in pituitary development.
The Prop1-cre is pituitary-specific, unlike other early pituitary markers, and is active
beginning at e11.5, after the initial formation of pituitary progenitors, with the peak of
its expression occurring during EPT, prior to lineage specification at e13.5 (9). Using the
Prop1-cre will allow us to conditionally delete or activate β-CATENIN solely within
Rathke’s pouch and at the correct timing in pituitary development so as to determine
whether pituitary progenitors are still sensitive to canonical WNT signaling activity
during this critical window.
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Figure 2.1 Summary of pituitary gland organogenesis.
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CHAPTER 3
MATERIALS & METHODS
Mice
The Institutional Committee on the Use and Care of Animals for the University of
South Carolina approved all experiments using mice. The Ctnnb1tm2Kem (β-catfx/fx) and
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo

(RosamTmG) mice were obtained from Jackson

Laboratory (71). Ctnnb1tm1Mmt (β-catGOF) mice were obtained from Mark Taketo at Kyoto
University via Santhakumar Manicassamy of Augusta University (70). Prop1-cre mice
were generated at the University of Michigan and are available from the Mutant Mouse
Resource and Research Center at the University of North Carolina at Chapel Hill (9).
Mice were fed without restriction and housed in specific pathogen free conditions with
automatic watering. Genotyping of mice was performed as previously reported
(9,70,71). The observation of a copulation plug was used to initiate the timing of
embryonic development; noon on the day the copulation was observed was then
defined as e0.5. Sexual dimorphism of the pituitary gland is not observed until after
birth, therefore, tissues were chosen for experiments without regard for sex (72). All
experiments were conducted using at least four mutant embryos. Embryos with the
genotype Prop1-cre; β-catfx/fx, for loss-of-function studies, or Prop1-cre; β-catGOF, for
gain-of-function studies, were designated as mutant embryos for their respective
studies. All other embryonic genotypes generated in the same litter as the mutant
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embryos were designated as wild-type embryos as all displayed a normal, healthy
pituitary phenotype.
Histology, Immunostaining, & RNAscope
Embryos at appropriate developmental time points were collected and fixed
overnight in 4% paraformaldehyde in phosphate buffered saline (PBS) at 4°C (73). The
fixative was removed and the embryos were washed in PBS, dehydrated into 100%
ethanol, permeabilized with methyl salicylate, and embedded in paraffin (73). Six µm
sections were generated from the embedded embryos, and select sections were chosen
for histology and stained with hematoxylin and eosin (H&E) (73).
Immunostaining information is included in Table 3.1, including antibody sources
and dilutions. All immunostaining experiments, except for pituitary hormone
immunostaining, were boiled in 10 mM citric acid, pH 6.0 for 10 minutes to retrieve
epitopes. Experiments utilizing horseradish peroxidase (HRP) for signal detection were
incubated in 50% Methanol and 1.5% Hydrogen Peroxide for 20 minutes at room
temperature to inactivate endogenous peroxidases. Immunostaining experiments
performed with mouse primary antibodies utilized blocking reagents from the M.O.M kit
as recommended by the manufacturer (Vector Laboratories), while primary antibodies
from other species utilized the blocking reagent from the tyramide signal amplification
(TSA) kit #22 dissolved in PBS (Thermo Fisher Scientific). Primary antibodies were
incubated overnight at 4° C in the TSA blocking reagent, followed by species-specific
secondary antibodies diluted 1:100 in TSA block and incubated for 30 minutes at room
temperature. For biotin-conjugated secondary antibodies, streptavidin conjugates (HRP,
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Alexa Fluor 488, or Alexa Fluor 594) were diluted 1:100 in TSA block and incubated for
30 minutes at room temperature (Thermo Fisher Scientific). Streptavidin HRP conjugates
were either followed by SIGMAFAST 3,3’-Diaminobenzidine (DAB) staining (Sigma) or
TSA with Alexa Fluor 488 (TSA Kit #22, Thermo Fisher Scientific) for 3 minutes.
Fluorescent detection methods were counterstained with 300 nM 4',6-diamidino-2phenylindole (DAPI) for 5 minutes before mounting in fluorescence mounting media,
while DAB detection was counterstained with 0.5% Methyl Green in 0.1 M Sodium
Acetate Buffer, pH 4.2 for 5 minutes at room temperature. The following
immunostaining protocols were previously reported: CCND2 (74), GFP (9), GH (39), Ki67
(17), LHX3 (20,25), LHβ (39), NOTCH2 (75), POMC (39), POU1F1 (27,76), PROP1 (10), SHH
(22), TPIT (3), and TSHβ (39).
In situ detection of β-CATENIN mRNA using the RNAscope 2.5 HD reagent kitBROWN (Advanced Cell Diagnostics) was performed according to manufacturer’s
recommendations and as previously reported on tissue sections cut at 6 μm thickness
(17). Both positive and negative probes supplied by the manufacturer were tested on all
tissues used for RNAscope. Tissues were counterstained with a 50% hematoxylin
solution.
Quantification Experiments
To determine the proportion of total cells expressing POU1F1 or SF1 at e14.5,
the total number of POU1F1- or SF1-positive cells in the forming anterior lobe was
counted in images of mid-sagittal sections from four wild-type embryos and four Prop1cre; β-catfx/fx mutant embryos using the cell counter feature in ImageJ. The total number
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of DAPI-stained nuclei in the forming anterior lobe was also counted for each image to
determine the total number of cells. Dividing the total number of POU1F1- or SF1positive cells by the number of DAPI-stained nuclei produced the proportion of POU1F1or SF1-positive cells for each embryo. The proportion of TBX19-positive cells was
similarly determined, with the exception that the proportion of TBX19-positive cells to
DAPI-stained nuclei was also determined in the intermediate lobe to differentiate
between anterior lobe corticotropes and intermediate lobe melanotropes. The
proportion of hormone positive cells for four wild-type and four Prop1-cre; β-catfx/fx
mutant embryos was determined using images of coronal sections at e18.5 as above.
The periluminal epithelium of Rathke’s pouch is composed of columnar cells in a
pseudostratified epithelium. These cells are morphologically distinct from the
epithelioid cells of the pituitary parenchyma in the anterior lobe. This morphological
distinction was used to select a region of interest containing the periluminal epithelium
on images of H&E stained wild-type and Prop1-cre; β-catGOF mutant embryos, and the
area of the region of interest was determined using ImageJ. For each of four wild-type
and four Prop1-cre; β-catGOF mutant embryos, five sections distributed across the left to
right axis of the pituitary gland were selected and the area of periluminal epithelium
was determined for each section along with an overall average area of periluminal
epithelium for each embryo.
To determine differences in expression of SOX9 at e14.5 in high and low βCATENIN expression regions of Prop1-cre; β-catGOF mutant embryos, β-CATENIN and
SOX9 double-immunostained images were analyzed in ImageJ. Regions of high β-
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CATENIN expression were used to determine regions of interest, and within these
regions the total number of SOX9-positive cells and the total number of DAPI-stained
nuclei were used to generate a proportion of SOX9-positive cells. Periluminal epithelial
cells with low β-CATENIN expression were used to determine regions of interest with
low β-CATENIN expression, and the proportion of SOX9-positive cells was also
determined within these regions of interest. Single images from four individual Prop1cre; β-catGOF mutant embryos were analyzed.
To determine differences in CCND2 expression at e16.5 between the
intermediate lobes of wild-type embryos and regions with high and low β-CATENIN
expression in Prop1-cre; β-catGOF mutant embryos, the proportion of CCND2-positive
cells was determined as above in each region. For wild-type embryos, single images
from four embryos were analyzed. For Prop1-cre; β-catGOF mutant embryos, three
images from each of four mutant embryos were analyzed. In Prop1-cre; β-catGOF mutant
embryos, the regions of high β-CATENIN expression where separated into large clusters,
which had an average of 209 cells and a range of 59 to 424 cells, and small clusters,
which had an average of 14 cells and a range of 3 to 57 cells.
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Table 3.1 Primary antibodies and detection methodology.
Peptide/
Protein
Target

Host
Species;
Mono- or
Polyclonal

βCATENIN

Rabbit;
Polyclonal

βCATENIN

Mouse;
Monoclon
al

CCND2

CK8/18

GFP

Rabbit;
Polyclonal

Guinea
Pig;
Polyclonal

Rabbit;
Polyclonal

Vendor

Abcam

BD

Santa Cruz

Abcam

Abcam

Dilution
Used

Detection Method

1:1000

Invitrogen
Goat anti-Rabbit Secondary
Antibody Biotin followed by
Invitrogen Streptavidin Alexa
Fluor™ 488 or Donkey anti-Rabbit
Secondary Antibody Alexa Fluor
594 for Double Immunostaining

1:100

Invitrogen
Goat anti-Mouse Secondary
Antibody Alexa Fluor 488 for
Double Immunostaining

1:200

Invitrogen
Goat anti-Rabbit Secondary
Antibody, Biotin followed by
Molecular Probes TSA
Amplification

1:50

Invitrogen
Goat anti-Guinea Secondary
Antibody Biotin followed by
Molecular Probes TSA
Amplification

1:1000

Invitrogen
Goat anti-Rabbit Secondary
Antibody Biotin followed by
Invitrogen Streptavidin Alexa
Fluor™ 488
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GH

Monkey;
Polyclonal

Ki67

Rabbit;
Polyclonal

National
Hormone and
Pituitary
Program,
NIDDK

Abcam

1:1000

Invitrogen
Goat anti-Rabbit Secondary
Antibody Biotin followed by
Invitrogen Streptavidin Alexa
Fluor™ 594 or Invitrogen
Streptavidin HRP and DAB

1:200

Invitrogen
Goat anti-Rabbit Secondary
Antibody Alexa Fluor 594

1:500

Invitrogen
Rabbit anti-Goat Secondary
Antibody Biotin followed by
Molecular Probes TSA
Amplification

1:500

Vector Laboratories Biotinylated
anti-Mouse Ig Reagent followed
by Molecular Probes TSA
Amplification

LEF1

Goat;
Polyclonal

Santa Cruz
Biotechnology

LHX3

Mouse;
Monoclon
al

Development
al Studies
Hybridoma
Bank, DSHB

Guinea
Pig;
Polyclonal

National
Hormone and
Pituitary
Program,
NIDDK

1:500

POMC

Rabbit;
Polyclonal

National
Hormone and
Pituitary
Program,
NIDDK

1:1500

POU1F1

Rabbit;
Polyclonal

Dr. Simon
Rhodes

LHβ

1:500
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Invitrogen
Goat anti-Rabbit Secondary
Antibody Biotin followed by
Invitrogen Streptavidin Alexa
Fluor™ 488 or Invitrogen
Streptavidin HRP and DAB
Invitrogen
Goat anti-Rabbit Secondary
Antibody Biotin followed by
Invitrogen Streptavidin Alexa
Fluor™ 594 or Invitrogen
Streptavidin HRP and DAB
Invitrogen Donkey anti-Rabbit
Secondary Antibody Alexa Fluor
594

PROP1

Guinea
Pig;
Polyclonal

SF1

Mouse;
Monoclon
al

SHH

Goat;
Polyclonal

SOX2

Rabbit;
Polyclonal

Dr. Aimee
Ryan

R&D Systems

R&D

ABclonal

1:100

Invitrogen
Goat anti-Guinea Secondary
Antibody Biotin followed by
Molecular Probes TSA
Amplification

1:250

Vector Laboratories Biotinylated
anti-Mouse Ig Reagent followed
by Molecular Probes TSA
Amplification

1:50

Invitrogen Rabbit anti-Goat Biotin
followed by Molecular Probes
TSA Amplification

1:200

Invitrogen
Goat anti-Rabbit Secondary
Antibody Biotin followed by
Molecular Probes TSA
Amplification

SOX9

Rabbit;
Monoclon
al

Abcam

1:100

TBX19

Rabbit;
Polyclonal

Dr. Jacques
Drouin

1:200

Rabbit;
Polyclonal

National
Hormone and
Pituitary
Program,
NIDDK

1:1000

TSHβ
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Invitrogen
Goat anti-Rabbit Secondary
Antibody Biotin followed by
Molecular Probes TSA
Amplification
Invitrogen
Goat anti-Rabbit Secondary
Antibody Biotin followed by
Invitrogen Streptavidin Alexa
Fluor™ 488 or Streptavidin Alexa
Fluor™ 594
Invitrogen
Goat anti-Rabbit Secondary
Antibody Biotin followed by
Invitrogen Streptavidin Alexa
Fluor™ 488 or Invitrogen
Streptavidin HRP and DAB

CHAPTER 4
RESULTS
Pituitary-Specific β-catenin Loss-of-Function
Since canonical WNT signaling is dependent on the nuclear accumulation of βCATENIN, we sought to inhibit canonical WNT signaling in pituitary progenitors using a
conditional null approach. The Ctnnb1tm2Kem (β-catfx) allele has loxP sites flanking exons 2
through 6 and results in a null allele in the presence of a cre recombinase (71). As
previously mentioned, the Prop1-cre mediates cre recombination beginning at e11.5 in
the pituitary progenitors of Rathke’s pouch (9). We crossed Prop1-cre; β-catfx/+ mice
with β-catfx/fx mice to produce Prop1-cre; β-catfx/fx mutant embryos with β-catenin
deleted in pituitary progenitors, as well as wild-type embryos, which were either Prop1cre negative or β-catfx/+.
In addition to functioning in the canonical WNT signaling pathway, β-CATENIN is
also present at adherens junctions and can persist at the membrane for many hours
following cre-mediated deletion (77). To determine the exact timing of β-CATENIN
protein deletion in Rathke’s pouch, we performed an immunostaining for β-CATENIN at
various embryonic time points [Fig. 4.1]. At e12.5, e14.5, and e18.5, β-CATENIN is
detectable throughout Rathke’s pouch in wild-type embryos, and its expression is
concentrated primarily at the cell membrane [Fig. 4.1A,C,E]. In Prop1-cre; β-catfx/fx
mutant embryos, small patches of cells in Rathke’s pouch are deficient in β-CATENIN at
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e12.5 [Fig. 4.1B]. By e14.5, the anterior lobe of mutant embryos displays significantly
reduced expression of β-CATENIN even though some protein is still detectable, primarily
in the developing intermediate lobe [Fig. 4.1D]. By e18.5, the anterior and intermediate
lobes in mutant embryos are almost entirely deficient in β-CATENIN [Fig. 4.1F]. There is
some detectable β-CATENIN in the anterior lobe of mutant embryos, but it is associated
with the endothelial cells of the invading vasculature [Fig. 4.1G,H]. These cells express
CD31 (PECAM) and are not derived from the population of PROP1-positive pituitary
progenitors (78).
Because β-CATENIN protein expression persists after cre recombination, we also
assayed β-catenin mRNA expression using RNAscope, a highly-sensitive in-situ
hybridization technique that has been previously used in the pituitary gland (17,79). At
e12.5 in wild-type embryos, β-catenin mRNA is detectable in the epithelium of Rathke’s
pouch; however, in the forming anterior lobe, β-catenin transcription is drastically
reduced [Fig. 4.1I]. This pattern of β-catenin expression is maintained in e14.5 wild-type
embryos, with higher levels of mRNA in the intermediate lobe than the anterior lobe
[Fig. 4.1K]. There are a few scattered cells in the anterior lobe with high β-catenin mRNA
expression, but these are likely associated with the developing vasculature which begins
to invade the anterior lobe at this time (80). In Prop1-cre; β-catfx/fx mutant embryos, βcatenin mRNA expression is reduced but not absent at e12.5 and is not detectable at
e14.5 [Fig. 4.1J,L]. These results suggest that the Prop1-cre successfully mediates
recombination at the β-catenin locus, resulting in reduced mRNA levels, despite the
continued presence of β-CATENIN protein at the cell membrane.
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Previous studies have shown that canonical WNT signaling can be disrupted with
the deletion of the β-catfx/fx locus even when β-CATENIN protein persists at the cell
membrane (77). Because LEF1 is a transcriptional target of canonical WNT signaling, we
assayed LEF1 expression in Prop1-cre; β-catfx/fx mutant embryos to determine if
canonical WNT signaling was disrupted despite the continued presence of β-CATENIN
protein. In wild-type embryos, LEF1 is expressed throughout the anterior lobe at e14.5,
but it is completely absent in Prop1-cre; β-catfx/fx mutant embryos at e14.5 [Fig 4.1M,N].
In e18.5 wild-type embryos, LEF1 expression is maintained throughout the anterior lobe,
but is still not observed in Prop1-cre; β-catfx/fx mutant embryos [Fig. 4.1O,P]. These
results demonstrate that despite the persistence of β-CATENIN at the membrane,
canonical WNT signaling is sufficiently disrupted in the developing anterior lobe of these
mutant embryos, due to the deletion of the β-catfx/fx locus by the Prop1-cre.
To determine if pituitary progenitors are affected by this loss of canonical WNT
signaling, we examined the expression of the three lineage-specific transcription factors:
POU1F1, TBX19, and SF1 [Fig. 4.2]. Because Pou1f1 is a direct transcriptional target of βCATENIN, POU1F1 expression should be significantly reduced in Prop1-cre; β-catfx/fx
mutant embryos. As expected, POU1F1 expression is almost absent in the anterior lobe
of Prop1-cre; β-catfx/fx mutant embryos at e14.5, compared to the high expression of
POU1F1 throughout the developing anterior lobe in wild-type embryos [Fig. 4.2A,D]. In
contrast, TBX19 expression is increased and SF1 expression appears unchanged in e14.5
mutant embryos [Fig. 4.2B,C,E,F].
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Next, we determined the proportion of total cells for each intermediate marker
of differentiation at e14.5 [Fig. 4.2G]. For POU1F1 and SF1, only cells in the anterior lobe
were counted; for TBX19, we separately determined the proportion of total cells for the
intermediate and anterior lobes to distinguish between the intermediate lobe
melanotropes and the anterior lobe corticotropes. The mean proportion of each cell
type from four individuals of each genotype was compared using a two-sample t-test
with unequal variance. As expected from a visual inspection of the immunostained
images, POU1F1 was significantly reduced in Prop1-cre; β-catfx/fx mutant embryos
compared to wild-type (P = 0.014). TBX19 expression has previously been shown to
increase when β-catenin is deleted in early pituitary progenitors (15); therefore, we
expected to see an increase in the proportion of TBX19-positive cells in Prop1-cre; βcatfx/fx mutant embryos compared to wild-type. In the anterior lobe, the mean
proportion of TBX19-positive cells was significantly increased in Prop1-cre; β-catfx/fx
mutant embryos (P = 0.041); in the intermediate lobe, however, the mean proportion of
TBX19 cells was not significantly different between the two genotypes (P = 0.557). The
mean proportion of SF1-positive cells was also increased in Prop1-cre; β-catfx/fx mutant
embryos compared to wild-type (P = 0.014). By e18.5, POU1F1 expression appears to
have recovered to some degree, as its expression is higher at e18.5 than at e14.5 in
Prop1-cre; β-catfx/fx mutant embryos, but it has not reached the expression level of wildtype embryos [Fig. 4.2H,K]. TBX19 expression is still increased in e18.5 mutant embryos
as compared to wild-type, whereas SF1 appears unchanged [Fig 4.2I,J,L,M].
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Based on the changes in expression of these three lineage-specific transcription
factors, we examined the expression of pituitary hormones in Prop1-cre; β-catfx/fx
mutant embryos to see if any of the hormones were likewise affected [Fig. 4.3]. As
expected, Prop1-cre; β-catfx/fx mutant embryos at e18.5 have reduced numbers of
somatotropes and thyrotropes, increased numbers of corticotropes, and similar
numbers of gonadotropes as compared to wild-type embryos [Fig. 4.3A-H]. The mean
proportion of each hormone cell type was compared between four wild-type and four
Prop1-cre; β-catfx/fx mutant embryos, using a two-sample t-test with unequal variance.
The proportion of GH- and TSHβ-positive cells was significantly reduced in Prop1-cre; βcatfx/fx mutant embryos (GH, P = 0.007; TSHβ, P = 0.0009), whereas the mean proportion
of POMC-positive cells in the anterior lobe was significantly increased (P = 0.021) [Fig.
4.3I]. Collectively, the results from Figures 4.2 and 4.3 demonstrate that pituitary
progenitors are sensitive to the loss of canonical WNT signaling during the period
following induction of Rathke’s pouch and before cell lineage commitment.
We hypothesized that the low proportion of POU1F1-positive cells in the
anterior lobe results from persistent β-CATENIN protein following cre-mediated
recombination. We immunostained wild-type embryos and Prop1-cre; β-catfx/fx mutant
embryos at e14.5 for both β-CATENIN and POU1F1 to determine whether POU1F1positive cells have persistent β-CATENIN expression [Fig. 4.4A-H]. In mutant embryos,
POU1F1-positive cells maintained β-CATENIN expression at the plasma membrane,
indicating that these cells do not have a complete loss of β-CATENIN.
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We then assayed the efficiency of β-catenin recombination by generating βcatfx/fx mice that also carry a cre reporter construct, RosamTmG (81). This ubiquitouslyexpressed, double-fluorescent reporter expresses the membrane-targeted tdTomato
(mT) prior to cre recombination and the membrane-targeted green fluorescent protein
(mG) after excision, allowing us to visualize cre activity (81). β-catfx/fx; RosamTmG/mTmG
mice were crossed with Prop1-cre; β-catfx/+ mice to generate Prop1-cre; β-catfx/fx;
RosamTmG/+ mutant embryos and wild-type littermates. We used expression of enhanced
green florescent protein (eGFP) from the recombined RosamTmG locus to visualize
recombination

in

Prop1-cre-positive

pituitary

glands.

In

wild-type

embryos,

immunostaining for GFP shows that membrane-bound eGFP is observed in all anterior
lobe cells at e14.5 [Fig. 4.4I-L], which demonstrates efficient recombination at the Rosa
locus by the Prop1-cre. In Prop1-cre; β-catfx/fx; RosamTmG/+ mutant embryos, we observed
small patches of eGFP-negative cells in the anterior lobe, demonstrating that in these
mutant embryos, some pituitary progenitors are able to escape recombination
mediated by the Prop1-cre [Fig. 4.4M-P]. Immunostaining for both GFP and POU1F1
shows that POU1F1 is expressed in these patches of eGFP-negative cells [Fig. 4.4N-P].
Therefore, the continued expression of POU1F1 after cre-mediated recombination is
likely the result of a failure to recombine the β-catenin locus in these cells, rather than
persistent protein expression.
We know from previous studies that PROP1 interacts with β-CATENIN to initiate
the transcription of POU1F1 (15). This same study also showed that LEF1 inhibits this
transcriptional activation of POU1F1 by PROP1/ β-CATENIN in a transiently transfected
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pituitary cell line (15). Given the negative regulation of POU1F1 by LEF1, we would
expect that LEF1-positive cells in the anterior lobe would not express POU1F1. We
performed double immunostaining for POU1F1 and LEF1 on wild-type embryos at e14.5
and found that our expectation was incorrect; POU1F1-positive cells can express LEF1
[Fig. 4.4Q-T]. Not all POU1F1-positive cells are LEF1-positive, but most LEF1-positive
cells express POU1F1. Therefore, LEF1 can be used as an indicator of canonical WNT
signaling activity in POU1F1-positive cells. Having established this association, we
examined the occurrence of POU1F1/LEF1 double-positive cells in Prop1-cre; β-catfx/fx
mutant embryos and found that the sparse POU1F1-positive cells also expressed LEF1
[Fig. 4.4U-X]. This result indicates that canonical WNT signaling is still active in these few
POU1F1-positive cells in the anterior lobe of Prop1-cre; β-catfx/fx mutant embryos, and
likely results from the presence of pituitary progenitor cells that did not undergo cremediated recombination of the β-catenin locus.
We know that PROP1 is required for POU1F1 transcription, but the relationship
between PROP1 and the other two lineage-specific factors is largely unknown (15).
Based on the known relationship between PROP1 and POU1F1, we performed
PROP1/POU1F1 double immunostaining on e14.5 wild-type embryos to determine if
their expression patterns overlapped in the developing anterior lobe [Fig. 4.5A-D]. As
expected, these two transcription factors appear in three different expression patterns
in the cells of the anterior lobe: cells that are only positive for PROP1, cells that are
positive for both PROP1 and POU1F1, and cells that are only positive for POU1F1 [Fig.
4.5B-D]. These results suggest a gradual conversion between the proliferating
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progenitors that are PROP1-positive to the anterior pituitary cells that are POU1F1positive, with an intermediate cell type that is positive for both PROP1 and POU1F1.
We then analyzed PROP1 and TBX19 via double immunostaining on e14.5 wildtype embryos to determine if PROP1 and TBX19 display similar overlapping expression
patterns [Fig. 4.5E-H]. In contrast to PROP1/POU1F1, pituitaries stained for
PROP1/TBX19 do not contain any cells that are positive for both PROP1 and TBX19 [Fig.
4.5F-H]. We could not perform similar analysis with PROP1 and SF1 due to incompatible
antibody issues, but we did perform double immunostaining for TBX19 and SF1 on e14.5
wild-type embryos and determined that TBX19 and SF1 do not have overlapping
expression patterns in any anterior lobe cells [Fig. 4.5I-L]. Collectively, these results
demonstrate that PROP1, despite being present in all pituitary progenitors, is limited to
the POU1F1 lineage after cell specification and does not appear to play a direct role in
the regulation of TBX19.
Previous studies have suggested a possible antagonistic relationship between
the three cell specification pathways in the developing anterior lobe (35,37). Our results
demonstrate that Prop1-cre; β-catfx/fx mutant embryos have decreased expression of
POU1F1 and two of its lineage cell types, somatotropes and thyrotropes, and a
corresponding increase in the expression of TBX19 and SF1, along with an increase in
corticotropes. This decrease in cells from one cell specification pathway accompanied by
a funneling of cells toward the other two cell specification pathways suggests that the
three cell specification pathways are maintained in a relative balance by some
regulatory mechanism. In order to explore this further, we determined the number of
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DAPI-positive nuclei in the anterior lobe of midsagittal sections from four individual
e14.5 pituitaries for each genotype. The total number of anterior pituitary cells in
mutant embryos is not significantly different compared to wild-type (P = 0.549),
demonstrating that despite the changes in the number of POU1F1-positive and TBX19positive cells, the total number of cells in the anterior lobe does not change [Fig. 4.5M].
Pituitary-Specific β-catenin Gain-of-Function
We know from previous studies that stimulating canonical WNT signaling at e9.5
or e10.5, using a β-catenin conditional gain-of-function allele (Ctnnb1tm1Mmt or β-catGOF),
results in pituitary dysmorphology and ACP formation (16,43). This is in contrast to
stimulating canonical WNT signaling at e14.5 or later, which has no observed effect on
pituitary morphology (16). We used the Prop1-cre and the β-catGOF allele to stimulate
canonical WNT signaling beginning at e11.5. Histological examination of e16.5 Prop1cre; β-catGOF mutant embryos compared with wild-type indicates that stimulating
canonical WNT signaling at this time point also results in highly dysmorphic pituitaries,
demonstrating that pituitary progenitors at e11.5 have not become refractory to
canonical WNT signaling [Fig. 4.6Aa-Ab].
β-CATENIN immunostaining at e16.5 indicates an increase in β-CATENIN
accumulation in Prop1-cre; β-catGOF mutant embryos compared with wild-type embryos
[Fig. 4.6Ac-Ad]. Despite the fact that the Prop1-cre is expressed in all pituitary
progenitors, this increased accumulation of β-CATENIN is not observed in all pituitary
cells. This pattern of β-CATENIN expression is similar to the foci or cell clusters with
increased β-CATENIN observed in both the Hesx1-cre; β-catGOF and Sox2creERT2; β-catGOF
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where β-CATENIN accumulated in some, but not all, pituitary cells, despite the presence
of cre expression and generation of the β-catGOF allele (16,43). Our results, in
conjunction with these two other β-catGOF mouse models, suggest that pituitary
progenitors have regulatory mechanisms that limit the accumulation of β-CATENIN from
the β-catGOF allele in some cells.
To determine when β-CATENIN begins to accumulate excessively in Prop1-cre; βcatGOF mutant embryos, we performed β-CATENIN immunostaining on wild-type and
mutant embryos at e12.5 and e14.5 [Fig. 4.6Ba-Bd]. At e12.5, small foci of increased βCATENIN expression were observed in Prop1-cre; β-catGOF mutant embryos. By e14.5,
we begin to see a highly dysmorphic pituitary phenotype accompanied by an increase in
the periluminal epithelial tissue and bulging regions that express high levels of βCATENIN. A similar pattern occurs with LEF1 expression, where small foci of LEF1positive cells were observed in Prop1-cre; β-catGOF mutant embryos at e12.5, while LEF1
is completely absent in wild-type embryos at this time [Fig. 4.6Be-Bf]. These ectopic
domains of LEF1 expression resemble developing foci in the Hesx1-cre; β-catGOF and
Sox2creERT2; β-catGOF models of ACP (16,43). At e14.5, LEF1 expression mirrors that of βCATENIN and is expressed in the same clusters of cells that are bulging out from the
periluminal epithelium, indicating that canonical WNT signaling is increased in these
regions [Fig. 4.6Bg-Bh]. These results demonstrate that the presence of ectopic
canonical WNT signaling and dysmorphic epithelial tissue begins as early as e12.5 and
becomes extensive by e14.5.
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Because the periluminal epithelial tissue of Prop1-cre; β-catGOF mutant embryos
appears expanded compared to wild-type, we determined the average area of
periluminal epithelial tissue from five sagittal sections across the lateral to medial axis
for four wild-type and four mutant embryos at e14.5, when the dysmorphology
becomes clearly apparent [Fig. 4.6C]. A representative region of periluminal epithelial
tissue is outlined in Figure 4.6Bc and Bd. Wild-type embryos had a mean periluminal
epithelial area of 27.5 ± 4.6 mm2, whereas Prop1-cre; β-catGOF mutant embryos had a
mean periluminal epithelial area of 118.7 ± 15.0 mm2, which is a statistically significant
difference in means (two-sample t test assuming unequal variances, P = 0.0003) and
equivalent to a 3.3-fold increase in periluminal epithelial tissue [Fig. 4.6C].
The cell clusters with high β-CATENIN expression in the Hesx1-cre; β-catGOF and
Sox2creERT2; β-catGOF models of ACP did not express pituitary hormones or other markers
of differentiation. We examined e18.5 Prop1-cre; β-catGOF mutant embryos for hormone
expression [Fig. 4.7A-H] and did not observe any pituitary hormones inside or outside of
the high β-CATENIN cell clusters. The intermediate markers of differentiation – that is,
POU1F1, TBX19, and SF1 – were also not expressed in any pituitary tissues of e18.5
Prop1-cre; β-catGOF mutant embryos [Fig. 4.8A-F].
At e14.5 in wild-type embryos, PROP1 is expressed in pituitary progenitors
around the lumen of Rathke’s pouch and in a subset of cells in the intermediate lobe
[Fig. 4.8G]. PROP1 expression in Prop1-cre; β-catGOF mutant embryos at this same time is
limited to the thin periluminal epithelium and is not expressed in the bulging regions of
periluminal epithelium that are characterized by high β-CATENIN expression [Fig. 4.8H].
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NOTCH2 is also expressed in the periluminal epithelium of e14.5 wild-type embryos [Fig.
4.8I], and its expression is dependent on PROP1 (75). In Prop1-cre; β-catGOF mutant
embryos, NOTCH2 is also expressed in the thin periluminal epithelium and not in the
bulging periluminal regions [Fig. 4.8J]. We hypothesized that high levels of β-CATENIN
inhibit the expression of PROP1, thus limiting its expression to regions of lower βCATENIN expression.
To confirm this hypothesis, we modified our immunostaining for β-CATENIN so
as to decrease the sensitivity. Under these modified conditions, β-CATENIN could not be
detected in wild-type embryos at e14.5, but it could still be detected in the dysmorphic
cell clusters of Prop1-cre; β-catGOF mutant embryos [Fig. 4.9A-B], which were the regions
that showed the strongest β-CATENIN accumulation with the unmodified staining
procedure [Fig. 4.6Ac-Ad]. Using these immunostaining conditions for β-CATENIN in
combination with PROP1 immunostaining, we confirmed that PROP1 is expressed in
pituitary epithelial cells that do not accumulate high levels of β-CATENIN [Fig. 4.9C-E].
Because these high β-CATENIN cell clusters do not express PROP1, lineage
specification factors, or pituitary hormones, it is possible that these cells are stuck in a
pituitary progenitor/stem cell stage. To determine whether these high β-CATENIN cell
clusters represent pituitary stem cells, we performed double immunostainings for the
stem cell markers LHX3, SOX2, and SOX9 in combination with β-CATENIN. Similar to
PROP1, LHX3 and SOX2 are only expressed in pituitary epithelial cells outside of the high
β-CATENIN cell clusters [Fig. 4.9F-O]. SOX9 is primarily expressed outside of the high βCATENIN cell clusters, but it has some scattered expression within the high β-CATENIN
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cell clusters at e14.5 [Fig. 4.9P-T]. To determine whether SOX9 expression is reduced in
the high β-CATENIN cell clusters as compared to the rest of the periluminal epithelium,
we determined the proportion of SOX9-positive cells in each region for four individual
Prop1-cre; β-catGOF mutant embryos [Fig. 4.9U]. The mean proportion in high β-CATENIN
cell clusters was 0.128 ± 0.039, which is significantly less than the mean proportion of
0.602 ± 0.165 in the remaining periluminal epithelium (two-sample t-test assuming
unequal variances, P = 0.008) [Fig. 4.9U]. These results suggest that the high β-CATENIN
cell clusters do not have a pituitary identity, as they do not express early, intermediate,
or definitive markers of pituitary cell types, with the exception of SOX9, which has
sharply reduced expression.
We next set out to determine if these Prop1-cre; β-catGOF dysmorphic pituitaries
resembled ACPs as have already been shown in Hesx1-cre; β-catGOF and Sox2creERT2; βcatGOF mice. Knowing that ACPs are slow-growing tumors characterized by a low
proliferative index, we used Ki67 to identify actively cycling cells and found that e14.5
Prop1-cre; β-catGOF mutant embryos do not express Ki67 in the bulging cell clusters
typical of high β-CATENIN expression [Fig. 4.10Aa-Ab], demonstrating that these cell
clusters are proliferating slowly. Ki67 was expressed in the thin periluminal epithelial
tissue characterized by low β-CATENIN expression, similar to its expression in the
epithelial tissue around the lumen of wild-type embryos.
CCND2 (CYCLIN D2) is necessary for the transition form G1 to S and can be used
as an indicator of proliferative cells. β-CATENIN is known to regulate CCND2
transcription through an interaction with PITX2, and CCND2 has been used as an
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indicator of canonical WNT signaling activity, similar to LEF1 (64). At e16.5, CCND2 is
primarily expressed in the epithelial layer around the lumen in wild-type embryos [Fig.
4.10Ac]. In Prop1-cre; β-catGOF mutant embryos, CCND2 is expressed in both the high βCATENIN cell clusters and in the epithelial tissue outside the high β-CATENIN cell
clusters [Fig.4.10Ad]. In examining this image, we noticed that CCND2 expression varied
in different regions of high β-CATENIN expression. In small patches of high β-CATENIN
expression (<50 cells), CCND2 was more highly expressed than in larger patches of high
β-CATENIN expression (>50 cells).
To determine the significance of this finding, we immunostained four wild-type
and four Prop1-cre; β-catGOF mutant embryos for CCND2 at e16.5 and determined the
mean proportion of CCND2-expressing cells in four different regions: the intermediate
lobe epithelium of wild-type embryos, the epithelial regions with low β-CATENIN in
Prop1-cre; β-catGOF mutant embryos, the large cell clusters with high β-CATENIN in
mutant embryos, and the small cell clusters with high β-CATENIN in mutant embryos. An
one-way ANOVA comparison of the mean proportion of CCND2-positive cells in these
four groupings showed that there was a significant difference between the groupings
(F(3, 12) = 20.5, P = 5.12 × 10-5). A post hoc t-test between wild-type epithelium and
mutant low β-CATENIN-expressing epithelium was not significantly different, suggesting
that these two regions are equivalent (two-sample t-test assuming unequal variances, P
= 0.175) [Fig. 4.10B]. Comparisons between the mutant low β-CATENIN-expressing
epithelium and both the large, high β-CATENIN cell clusters (two-sample t-test assuming
unequal variances, P = 0.0007) and the small, high β-CATENIN cell clusters (two-sample
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t-test assuming unequal variances, P = 0.002) were significantly different, suggesting
that CCND2 is up-regulated in the small, high β-CATENIN cell clusters and downregulated in the large, high β-CATENIN cell clusters [Fig. 4.10B]. Our analysis of Ki67 and
CCND2 expression patterns indicates that large, high β-CATENIN cell clusters have a
reduced proliferative capacity.
ACP tumors from Hesx1-cre; β-catGOF mice are characterized by the expression of
CK8 and CK18, which are indicative of an oral ectoderm identity (16). We performed
immunostaining in wild-type and Prop1-cre; β-catGOF mutant embryos at 18.5 with an
antibody that recognizes both CK8 and CK18, in combination with β-CATENIN
immunostaining to identify regions of high β-CATENIN expression [Fig. 4.10Ca-Cb]. We
observed CK8/18 expression throughout the pituitary gland of wild-type embryos,
demonstrating that this epithelial marker does not discriminate between the epithelium
of the intermediate lobe and the parenchyma of the anterior lobe. CK8/18 is expressed
in Prop1-cre; β-catGOF mutant embryos in the epithelia outside of the high β-CATENIN
cell clusters, which is similar to its expression in wild-type embryos. This pattern
resembles that of other pituitary markers, which are not expressed in regions with high
β-CATENIN expression.
Sox2creERT2; β-catGOF mice also form ACP tumors where cell foci with high βCATENIN expression express signaling factors, including SHH (43). Because SHH is
excluded from the portion of oral epithelium that becomes Rathke’s pouch, it is not
normally expressed in wild-type pituitaries (23). We performed double immunostaining
for SHH and β-CATENIN at e18.5 in wild-type and Prop1-cre; β-catGOF mutant embryos
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[Fig. 4.10Cc-Cd] and observed that SHH is expressed in the regions of high β-CATENIN
expression in mutant embryos. Although SHH is not a definitive marker for oral
ectoderm, SHH expression in the high β-CATENIN cell clusters is suggestive of a
conversion from a pituitary identify back to a more oral ectoderm-like state.

39

Figure 4.1 Reduction in β-CATENIN expression and canonical WNT signaling in Prop1-cre;
β-catfx/fx embryos.
[A-F] β-CATENIN immunostaining (green) on e12.5 [A-B] and e14.5 [C-D] sagittal sections
and e18.5 coronal sections [E-F], counterstained with DAPI (blue). [A, C, E] Wild-Type
and [B, D, F] Prop1-cre; β-catfx/fx. Dotted line in [A] indicates Rathke’s pouch. Arrow in
[B] indicates a small domain with no β-CATENIN expression. Dotted line in [E] indicates
the pituitary anterior and intermediate lobes. [G-H] β-CATENIN (green) and CD31 (red)
double immunostaining on e18.5 coronal sections, counterstained with DAPI (blue).
White dotted line indicates anterior lobe; red dotted line indicates intermediate lobe.
[G] Wild-Type and [H] Prop1-cre; β-catfx/fx. Arrow in [H] indicates an endothelial cell with
β-CATENIN expression. Cells with bright green signal in [G] are autofluorescent red
blood cells. [I-L] β-catenin RNAscope (brown) on e12.5 [I-J] and e14.5 [K-L] sagittal
sections, counterstained with hematoxylin (blue). [I, K] Wild-Type. [J, L] Prop1-cre; βcatfx/fx. Arrow in [I] indicates a region of the developing anterior lobe with low
expression of β-catenin [M-P] LEF1 immunostaining (green), counterstained with DAPI
(blue) on e14.5 sagittal sections [M-N] and e18.5 coronal sections [O-P]. [M, O] WildType and [N, P] Prop1-cre; β-catfx/fx. Arrow in [N] indicates the anterior lobe where LEF1
is not observed. All scale bars equal 100 µm.

40

*

*

*

Figure 4.2 Prop1-cre; β-catfx/fx embryos have a reduction in POU1F1 expression.
[A-C] Wild-Type and [D-F] Prop1-cre; β-catfx/fx e14.5 sagittal sections
immunostained for [A, D] POU1F1, [B, E] TBX19, and [C, F] SF1. [G] Graph of the
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proportion of each marker of differentiation in wild-type and Prop1-cre; β-catfx/fx
embryos at e14.5. Error bars represent standard deviation; asterisks indicate p <
0.05 in a two-sample t-test with unequal variance. [H-J] Wild-Type and [K-M]
Prop1-cre; β-catfx/fx e18.5 coronal sections immunostained for [H, K] POU1F1, [I,
L] TBX19, and [J, M] SF1. Scale bars equal 100 µm for all images.
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Figure 4.3 Prop1-cre; β-catfx/fx embryos have a reduction in the POU1F1 lineage.
[A-D] Wild-type and [E-H] Prop1-cre; β-catfx/fx e18.5 coronal sections immunostained for
[A, E] GH, [B, F] TSHβ, [C, G] POMC, and [D, H] LHβ. [I] Graph of the proportion of each
hormone cell type in wild-type and Prop1-cre; β-catfx/fx embryos at e18.5. Error bars
represent standard deviation; asterisks indicate p < 0.05 in a two-sample t-test with
unequal variance. All scale bars equal 100 µm.
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Figure 4.4 POU1F1 is expressed in cells that maintain β-CATENIN expression.
[A-H] POU1F1 [red and B, F] and β-CATENIN [green and C, G] double immunostaining on
e14.5 coronal sections. [A-D] Wild-type and [E-H] Prop1-cre; β-catfx/fx. [B-D] are higher
magnification images of the boxed region in [A], and [D] is an overlay of individual gray
scale channels presented in [B-C]. White arrows in [B-D] highlight the same cell in each
panel with POU1F1 and β-CATENIN expression. [F-H] are higher magnification images of
the boxed region in [E], and [H] is an overlay of individual gray scale channels presented
in [F-G]. White arrows in [F-H] highlight the same cell in each panel with POU1F1 and βCATENIN expression. [I-P] POU1F1 [red and J, N] and GFP [green and K, O] double
immunostaining on e14.5 coronal sections. [I-L] Wild-type (Prop1-cre; β-catfx/+;
RosamTmG/+) and [M-P] Prop1-cre; β-catfx/fx; RosamTmG/+. [J-L] are higher magnification
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images of the boxed region in [I], and [L] is an overlay of individual gray scale channels
presented in [J-K]. White arrows in [J-L] highlight the same cell in each panel with
POU1F1 and GFP expression. [N-P] are higher magnification images of the boxed region
in [M], and [P] is an overlay of individual gray scale channels presented in [N-O]. White
arrows in [N-P] highlight the same cell in each panel with POU1F1, but lacking GFP
expression, suggesting an absence of Prop1-cre mediated recombination. [Q-X] POU1F1
[red and R, V] and LEF1 [green and S, W] double immunostaining on e14.5 sagittal
sections. [Q-T] Wild-type and [U-X] Prop1-cre; β-catfx/fx. [R-T] are higher magnification
images of the boxed region in [Q], and [T] is an overlay of individual gray scale channels
presented in [R-S]. White arrows in [R-T] highlight the same cell in each panel with
POU1F1 and LEF1 expression. [V-X] are higher magnification images of the boxed region
in [U], and [X] is an overlay of individual gray scale channels presented in [V-W]. White
arrows in [V-X] highlight the same cell in each panel with POU1F1 and LEF1 expression.
Images with blue are counterstained with DAPI. Scale bars equal 100 µm for all images.
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Figure 4.5 After cell specification, PROP1 is limited to POU1F1 lineage cell types.
[A-D] PROP1 [green and B] and POU1F1 [red and C] double immunostaining on e14.5
sagittal sections. [B-D] are higher magnification images of the boxed region in [A], and
[D] is the overlay of individual gray scale channels presented in [B-C]. White arrows in
[B-D] highlight the same cell in each panel with PROP1 and POU1F1 expression. [E-H]
PROP1 [green and F] and TBX19 [red and G] double immunostaining on e14.5 sagittal
sections. [F-H] are higher magnification images of the boxed region in [E], and [H] is the
overlay of individual gray scale channels presented in [F-G]. White arrows in [F-H]
highlight the same cell in each panel with TBX19, but lacking PROP1 expression,
suggesting that PROP1 is not expressed in cells that express TBX19. [I-L] SF1 [green and
J] and TBX19 [red and K] double immunostaining on e14.5 sagittal sections. [J-L] are
higher magnification images of the boxed region in [I], and [L] is the overlay of individual
gray scale channels presented in [J-K]. White arrows in [J-L] highlight the same cell in
each panel with TBX19, but lacking SF1 expression, suggesting that TBX19 is not
expressed in cells that express SF1. All scale bars equal 100 µm. [M] Graph of the total
number of cells in the anterior pituitaries of wild-type and Prop1-cre; β-catGOF/+ e14.5
pituitaries. Error bars represent standard deviation.
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Figure 4.6 Prop1-cre; β-catGOF/+ embryos have dysmorphic pituitaries with increased
canonical WNT signaling and periluminal epithelium.
[Aa-Ab] H&E staining of wild-type [Aa] and Prop1-cre; β-catGOF/+ [Ab] e16.5 coronal
sections. [Ac-Ad] β-CATENIN immunostaining (green) on wild-type [Ac] and Prop1-cre; βcatGOF/+ [Ad] e16.5 coronal sections, counterstained with DAPI (blue). [Ba-Bb] β-CATENIN
immunostaining (red) on wild-type [Ba] and Prop1-cre; β-catGOF/+ [Bb] e12.5 sagittal
sections, counterstained with DAPI (blue). Arrow in [Bb] indicates a small focus of
increased β-CATENIN expression, in contrast to the uniform level of β-CATENIN
expression observed in [Ba]. [Bc-Bd] β-CATENIN immunostaining (green) on wild-type
[Bc] and Prop1-cre; β-catGOF/+ [Bd] e14.5 sagittal sections, counterstained with DAPI.
Dotted lines in [Bc-Bd] indicate examples of periluminal epithelium used for area
measurements in [C]. [Be-Bh] LEF1 immunostaining (red) on wild-type [Be, Bg] and
Prop1-cre; β-catGOF/+ [Bf, Bh] e12.5 [Be-Bf] and e14.5 [Bg-Bh] sagittal sections,
counterstained with DAPI (blue). Arrow in [Bf] indicates a small focus of ectopic LEF1
expression, in contrast to the lack of LEF1 expression in [Be]. Scale bars equal 100 µm
for all images. [C] Graph of periluminal epithelial area in wild-type and Prop1-cre; βcatGOF/+ e14.5 pituitaries. Error bars represent standard deviation; asterisk indicates p <
0.05 in a two-sample t-test with unequal variance.
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Figure 4.7 Prop1-cre; β-catGOF/+ embryos do not express pituitary hormones.
[A-H] Immunostaining for pituitary hormones (brown) on e18.5 coronal sections,
counterstained with Methyl Green (blue). [A, C, E, G] Wild-type embryos and [B, D, F, H]
Prop1-cre; β-catGOF/+ embryos immunostained for [A, B] POMC, [C, D] LHβ, [E, F] GH, and
[G, H] TSHβ. Scale bars equal 100 µm for all images.
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Figure 4.8 Prop1-cre; β-catGOF/+ embryos do not express lineage-specific transcription
factors.
[A-F] Immunostaining for lineage specific transcription factors (red) on e16.5 coronal
sections, counterstained with DAPI (blue). [A, C, E] Wild-type embryos and [B, D, F]
Prop1-cre; β-catGOF/+ embryos immunostained for [A, B] TBX19, [C, D] SF1, and [E, F]
POU1F1. [G-J] Immunostaining on e14.5 sagittal sections of [G, I] wild-type and [H, J]
Prop1-cre; β-catGOF/+ embryos, counterstained with DAPI (blue). [G-H] PROP1 (red) and
[I-J] NOTCH2 (green). Arrow in [H] indicates a region of periluminal epithelium with
PROP1 expression. Arrow in [I] indicates NOTCH2 expression in wild-type periluminal
epithelium. Arrow in [J] indicates a bulging region of periluminal epithelium with no
NOTCH2 expression. Scale bars equal 100 µm for all images.
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Figure 4.9 Regions of high β-CATENIN expression in Prop1-cre; β-catGOF/+ embryos do not
express pituitary progenitor markers.
[A] PROP1 immunostaining (red) on a wild-type e14.5 sagittal section, counterstained
with DAPI (blue). [B-E] PROP1 [red and C] and β-CATENIN [green and D] double
immunostaining on an e14.5 Prop1-cre; β-catGOF/+ sagittal section. [C-E] are higher
magnification images of the boxed region in [B], and [E] is the overlay of individual gray
scale channels presented in [C-D]. [F] LHX3 immunostaining (green) on a wild-type e14.5
sagittal section, counterstained with DAPI (blue). [G-J] LHX3 [green and H] and βCATENIN [red and I] double immunostaining on a Prop1-cre; β-catGOF/+ e14.5 sagittal
section. [H-J] are higher magnification images of the boxed region in [G], and [J] is the
overlay of individual gray scale channels presented in [H-I]. [K] SOX2 immunostaining
(red) on a wild-type e16.5 coronal section, counterstained with DAPI (blue). [L-O] SOX2
[red and M] and β-CATENIN [green and N] double immunostaining on a Prop1-cre; βcatGOF/+ e16.5 coronal section. [M-O] are higher magnification images of the boxed
region in [L], and [O] is the overlay of individual gray scale channels presented in [M-N].
[P] SOX9 immunostaining (red) on a wild-type e14.5 sagittal section, counterstained
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with DAPI (blue). [Q-T] SOX9 [red and R] and β-CATENIN [green and S] double
immunostaining on a Prop1-cre; β-catGOF/+ e14.5 sagittal section. [R-T] are higher
magnification images of the boxed region in [Q], and [T] is the overlay of individual gray
scale channels presented in [R-S]. The red dotted line in [T] indicates a periluminal
region with low β-CATENIN expression, while the yellow dotted line represents a
periluminal region with high β-CATENIN expression. These regions are examples of areas
used to determine the proportion of SOX9-expressing cells in low and high β-CATENIN
expressing regions. [B, G, L, Q] Blue staining represents DAPI counterstain. Scale bars
equal 100 µm for all images. [U] Graph of the proportion of SOX9 expressing cells in low
and high β-CATENIN regions of Prop1-cre; β-catGOF/+ e14.5 sagittal sections. Error bars
represent the standard deviation; asterisk indicates p < 0.05 in a two-sample t-test with
unequal variance.
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Figure 4.10 Regions of high β-CATENIN expression in Prop1-cre; β-catGOF/+ embryos are
quiescent and do not express markers associated with a pituitary fate.
[Aa-Ab] Ki67 immunostaining (red) on e14.5 wild-type [Aa] and Prop1-cre; β-catGOF/+
[Ab] sagittal sections, counterstained with DAPI (blue). Arrow in [Ab] indicates
proliferating cells in the periluminal epithelium, typically characterized by low βCATENIN expression. [Ac-Ad] CCND2 (red) and β-CATENIN (green) double
immunostaining on e16.5 wild-type [Ac] and Prop1-cre; β-catGOF/+ [Ad] coronal sections,
counterstained with DAPI (blue). Red dashed line in [Ac] is an example of the
intermediate lobe region used to determine the proportion of CCND2 expressing cells.
Red dashed line in [Ad] represents an example of the periluminal epithelium with low βCATENIN expression, the yellow dashed line represents an example of a large cell cluster
with high β-CATENIN expression, and the white dashed line represents an example of a
small cell cluster with high β-CATENIN expression. [B] Graph of the proportion of
CCND2-expressing cells in the wild-type intermediate lobe and Prop1-cre; β-catGOF/+
periluminal epithelium. Error bars represent the standard deviation; asterisks indicate p
< 0.05 in a two-sample t-test with unequal variance. [Ca-Cb] CK8+18 (green) and βCATENIN (red) double immunostaining on e18.5 wild-type [Ca] and Prop1-cre; β-catGOF/+
[Cb] coronal sections, counterstained with DAPI (blue). [Cc-Cd] SHH (green) and βCATENIN (red) double immunostaining on e18.5 wild-type [Cc] and Prop1-cre; β-catGOF/+
[Cd] coronal sections, counterstained with DAPI (blue). Arrow in [Cd] indicates a high βCATENIN cell cluster with SHH expression. Scale bars equal 100 µm for all images.
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CHAPTER 5
DISCUSSION
Pituitary gland organogenesis is characterized by a series of discrete stages,
beginning with the induction of Rathke’s pouch and culminating in a fully-functioning,
hormone-secreting pituitary gland. In the first stage, the induction of pituitary
progenitors occurs in Rathke’s pouch between e9.5 and e10.5 [Fig. 5.1A]. These pituitary
progenitors are characterized by the expression of early pituitary transcription factors,
including LHX3, ISL1, HESX1, PITX1, and SOX2. The second stage begins at e11.5 when
Rathke’s pouch is closed off and completely separated from the oral ectoderm. During
this stage, pituitary progenitors begin to exit the cell cycle and undergo an epithelial-toparenchymal transition (EPT) from the epithelia of Rathke’s pouch to the parenchyma of
the anterior pituitary [Fig. 5.1A]. PROP1 is expressed in pituitary progenitors during this
second stage and is required for the EPT that will form the anterior lobe. The third stage
begins when lineage-specific transcription factors – POU1F1, TBX19, and SF1 – are
expressed in pituitary parenchyma [Fig. 5.1A]. These transcription factors are necessary
for the differentiation of specific cell types from the common pool of PROP1-positive
pituitary progenitors. The last stage of pituitary development is terminal differentiation,
in which the cells of the anterior lobe begin to express cell type-specific hormones.
Canonical WNT signaling through β-CATENIN has been shown to affect pituitary
organogenesis when deleted or stimulated in early pituitary progenitors, prior to the
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induction of the second stage of pituitary development at e11.5 (15,16). In contrast,
deleting or stimulating β-CATENIN during the third or fourth stages of pituitary
development has no observable effect on the developing pituitary gland. What is not yet
known is how pituitary progenitors respond to canonical WNT signaling during the
second stage of pituitary development. We used the Prop1-cre, which is active starting
at e11.5, to perform loss- and gain-of-function studies on β-CATENIN during this critical
time point. Our results show that pituitary progenitors are still sensitive to regulation by
canonical WNT signaling as they exit the cell cycle and undergo an EPT, suggesting that
pituitary progenitors at this stage have not yet committed to specific cell lineages and
remain responsive to external signals, including canonical WNT signaling.
β-catenin Loss-of-Function During EPT
Previous studies used the Pitx1-cre to conditionally delete β-CATENIN in early
pituitary progenitors at e9.5, prior to Rathke’s pouch invagination (15). This generated
Pitx1-cre; β-catfx/fx mutant embryos that do not express POU1F1, GH, TSHβ, or PRL.
Similarly, our results demonstrate that Prop1-cre; β-catfx/fx mutant embryos have
reduced expression of POU1F1, GH, and TSHβ [Fig. 5.1B]. Prolactin expression was not
determined for Prop1-cre; β-catfx/fx mutant embryos because PRL is not detectible via
immunostaining at e18.5, unlike the other anterior pituitary hormones.
In wild-type embryos, PROP1 interacts with β-CATENIN to initiate POU1F1
transcription [Fig. 5.1A] (15). As there are still a number of POU1F1-positive cells in
Prop1-cre; β-catfx/fx mutant embryos, despite a drastic decrease in β-CATENIN
expression, we wanted to further examine these POU1F1-positive cells to determine if it
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is possible to initiate POU1F1 transcription in the absence of β-CATENIN. Double
immunostaining for POU1F1 and β-CATENIN at e14.5 showed that the few POU1F1positive cells remaining are positive for β-CATENIN, confirming that β-CATENIN is
required to initiate POU1F1 transcription.
The presence of β-CATENIN in Prop1-cre; β-catfx/fx cells could result from the
persistence of a pool of β-CATENIN protein in the cell, such as at the cell membrane,
following the generation of the β-catenin null allele at e11.5 (77). However, a more
likely possibility is that in some Prop1-cre; β-catfx/fx mutant cells, the Prop1-cre
transgene is not transcribed and the β-catenin null allele is not generated. Regardless of
the mechanism, the presence of LEF1 in a subset of Prop1-cre; β-catfx/fx mutant cells
demonstrates that canonical WNT signaling is still active in these cells and also implies
that β-CATENIN must be available to promote POU1F1 transcription. In cell culture, LEF1
inhibits the transcription of a POU1F1 reporter construct, and Lef1-/- mice have an
increase in the POU1F1 lineage (15). Additionally, miRNA-26b inhibits LEF1 expression,
which results in an increase in POU1F1 expression (82). However, our results
demonstrate that in vivo, LEF1 and POU1F1 can be expressed simultaneously in the
same cell, implying that LEF1 expression does not preclude POU1F1 expression.
In wild-type embryos, the Prop1-cre sufficiently targets an eGFP reporter
construct in the Rosa locus and generates membrane-bound eGFP in all anterior lobe
cells (9). For some reason, not all anterior lobe cells in Prop1-cre; β-catfx/fx mutant
embryos express eGFP. This result implies that these cells have differentiated without
activating the Prop1-cre transgene. In support of this possibility, Ames dwarf mice,
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which are homozygous null for Prop1, have small patches of cells that express POU1F1
and differentiate into the POU1F1 lineage cell types (33). Therefore, it is possible for
some pituitary progenitors to differentiate into the POU1F1 lineage without ever
activating Prop1. We think that this subset of eGFP-negative, POU1F1-positive cells in
Prop1-cre; β-catfx/fx mutant embryos have not activated the Prop1-cre transgene, and
thus not generated the β-catenin null allele. How POU1F1 is activated in the absence of
PROP1 is unknown, but these results imply an alternative mechanism for POU1F1
transcription other than by a PROP1/β-CATENIN complex.
Generally, canonical WNT signaling and β-CATENIN are associated with actively
promoting EMT during development and cancer metastasis (41). In the pituitary gland,
however, loss of β-catenin does not inhibit the EPT necessary to form the anterior lobe,
as Prop1-cre; β-catfx/fx mutant embryos have an anterior lobe that is morphologically
similar to wild-type embryos. This morphology is in contrast to Prop1-/- pituitaries, which
have a dysmorphic pituitary gland, a reduced anterior lobe, and an increase in luminal
epithelium, demonstrating that the progenitors in Prop1-/- pituitaries are unable to
complete an epithelial-to-parenchymal transition (31). Although PROP1 and β-CATENIN
form a complex to promote POU1F1 transcription, it appears that PROP1, but not βCATENIN, is required to promote EPT.
Similar to previous results in Pitx1-cre; β-catfx/fx mutant embryos, Prop1-cre; βcatfx/fx mutant embryos have a significant increase in TBX19 expression [Fig. 5.1B] (15).
SF1 expression was not altered in Pitx1-cre; β-catfx/fx mutant embryos, whereas we
found a small but significant increase in SF1 expression in Prop1-cre; β-catfx/fx mutant
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embryos [Fig. 5.1B]. The difference in SF1 expression between the two studies may
result from variations in small sample sizes and may not represent a meaningful
difference. However, the increase in TBX19, and possibly SF1, when POU1F1 expression
is reduced suggests that a fate switch occurs in pituitary progenitors in the absence of
canonical WNT signaling.
Lineage-tracing studies using the Prop1-cre have shown that all pituitary
hormone cell types arise from a common pool of PROP1-positive pituitary progenitors
(9). Canonical WNT signaling activity in a subset of pituitary progenitors likely promotes
the POU1F1 lineage. We know from previous studies that pituitary hormone cell types
can be generated from embryonic stem cells in vitro (83–85). The primary hormone
produced in these cultures is ACTH, which requires TBX19 expression. The percentage of
GH- and POU1F1-expressing cells can be increased by adding a small molecule that
stimulates canonical WNT signaling, supporting the need for canonical WNT signaling in
pituitary progenitors to promote the POU1F1 lineage (83).
How a subset of pituitary progenitors receives a canonical WNT signal in vivo to
promote the POU1F1 lineage is unknown. Multiple WNT ligands are expressed in the
pituitary progenitors of Rathke’s pouch, including WNT4, WNT5A, WNT11, and WNT16
(1,21). Of these WNTs, only WNT4 has been shown to affect the differentiation of
hormone cell types, as Wnt4-/- embryos exhibit a decrease in the number of POU1F1
lineage cells (21). What is not known, however, is whether WNT4 is acting via a
canonical or non-canonical pathway. As we know from previous studies, it is the
combination of ligand and receptor that determines whether the WNT signaling
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pathway that is activated is canonical or non-canonical (59–61). Further studies are
needed to determine the specific WNT ligand and receptor combination that is
necessary for promoting canonical WNT signaling in the POU1F1 lineage.
As previously discussed, our results suggest that a fate switch occurs in pituitary
progenitors when there is a reduction in one cell specification pathway. This possibility
is also suggested in Tbx19-/- embryos, which generate gonadotropes and thyrotropes in
the intermediate lobe instead of the usual melanotropes, and Hes1-/- embryos, which
similarly result in a loss of melanotropes and replacement with somatotropes in the
intermediate lobe (35,37). By performing double immunostaining experiments, we were
able to determine that although PROP1 is expressed in all pituitary progenitors prior to
cell fate commitment, PROP1 is then limited to the POU1F1 lineage after this point. We
were also able to show that TBX19 and SF1 are not co-expressed in anterior pituitary
cells at e14.5, during the lineage commitment stage of pituitary development. Together,
these results suggest that the three cell specification pathways diverge from a common
pituitary progenitor cell type into three distinct pathways that do not intersect (9).
Despite the expression changes in POU1F1, TBX19, and SF1 in Prop1-cre; β-catfx/fx
mutant pituitaries at e14.5, the total number of cells in these pituitaries is not
significantly different compared to wild-type pituitaries. This suggests that a regulatory
mechanism exists through which the three cell specification pathways are kept in
balance such that the loss of one pathway results in the channeling of more cells
towards the other two pathways. We know from previous studies that interfering with
pituitary organogenesis during or after the cell commitment stage has no effect on
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anterior pituitary cells (15,16). However, our results show that pituitary progenitors are
still responsive to external regulation during EPT, when pituitary progenitors are PROP1positive and have not yet committed to one of the three cell specification pathways.
Further studies will be needed to determine the mechanism through which pituitary
progenitors are regulated prior to committing to a specific cell fate and how the loss of
one cell specification pathway affects the regulation of other pituitary progenitors.
β-catenin Gain-of-Function During EPT
Activating mutations in β-catenin have been shown to generate ACP tumors
when stimulated in early pituitary progenitors, using the Hesx1-cre, and in adult
pituitary stem cells, using the Sox2creERT2 (16,43). We have shown that pituitary
progenitors are still sensitive to canonical WNT signaling during EPT and that gain-offunction mutations in β-catenin at this stage in pituitary development also result in an
ACP-like phenotype. This dysmorphology is characterized by a more than threefold
increase in epithelial tissue in the developing pituitary gland along with the
accumulation of β-CATENIN in foci that branch off from the luminal epithelium. The first
few foci that appear at e12.5 are small and sparse, but they quickly expand to large
clusters of cells that branch off from the luminal epithelium by e14.5.
Based on this large accumulation of periluminal epithelium, we believe that
introducing a gain-of-function mutation in β-CATENIN at this stage inhibits the EPT
necessary for anterior lobe formation. In support of this theory, the cells adjacent to the
periluminal epithelium have the morphology of head mesenchyme, rather than that of
anterior lobe parenchyma. Additionally, SOX9 is normally expressed weakly in the
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luminal epithelium and strongly in the posterior lobe and head mesenchyme
surrounding Rathke’s pouch [Fig. 4.9P]. The strong expression of SOX9 in the cells
adjacent to the periluminal epithelium in Prop1-cre; β-catGOF mutant pituitaries suggests
that these cells are of head mesenchyme origin and not of pituitary progenitor origin.
Canonical WNT signaling through β-CATENIN is known to promote EMT in many
tissues, such as in the primitive streak during gastrulation and in the metastasis of colon
cancer cells (41). The inhibition of EPT in the pituitary gland as a result of the β-catGOF
protein is unusual. We know that PROP1 is necessary for promoting EPT through the
transcription of Zeb2, Gli2, Mmp2, Mmp3, and Mmp16, while inhibiting the transcription
of Cldn23 (Claudin23) and CDH1 (E-cadherin) (30). Notch2 transcription is also
stimulated by PROP1, and NOTCH signaling is known to promote EMT in cancer and
development (30,41). Since both PROP1 and NOTCH2 are inhibited by the high levels of
β-CATENIN in Prop1-cre; β-catGOF mutant embryos, we think that the transcriptional
profile necessary for EPT is not expressed in these embryos, thus preventing the
formation of an anterior lobe.
The production of the β-catGOF protein in PROP1-positive pituitary progenitors
prevents the differentiation of hormone cell types. We were unable to detect individual
hormones or the lineage specific markers POU1F1, TBX19, and SF1 in Prop1-cre; β-catGOF
mutant pituitaries [Fig. 5.1C]. Additionally, the large cell clusters that expressed high
levels of β-CATENIN did not express the pituitary progenitor transcription factors SOX2,
LHX3, and PROP1, and they had a decrease in SOX9 expression. These results
demonstrate that persistent β-catGOF protein in pituitary progenitors shifts these cells
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away from a pituitary identity. Similarly, ACP tumors do not produce pituitary
hormones, but they can become calcified and produce the enamel proteins
characteristic of teeth (13). This suggests that ACPs could represent a reversion of
pituitary progenitors to an earlier, more oral ectoderm-like fate.
CK8 and CK18 were previously used to identify Hesx1-cre; β-catGOF/+ tumors as
having an epithelial phenotype, consistent with oral ectoderm (16). We used an
antibody that recognizes both CK8 and CK18 to characterize wild-type and Prop1-cre; βcatGOF mutant pituitaries. CK8/CK18 are expressed throughout the intermediate and
anterior lobes of wild-type pituitaries, demonstrating that this epithelial marker is part
of a normal embryonic pituitary identity. In Prop1-cre; β-catGOF mutant pituitaries, the
regions with high β-CATENIN expression did not express CK8/CK18, consistent with a
shift of these cells away from a normal pituitary identity. These cell clusters also
expressed SHH, which is normally expressed in the oral ectoderm but is excluded from
the invaginating Rathke’s pouch [Fig. 5.1C] (23). In order to confirm that Prop1-cre; βcatGOF mutant pituitaries have reverted to an oral ectoderm state, further studies will
need to be completed to identify markers that can discriminate between embryonic oral
ectoderm and pituitary progenitors [Fig. 5.1C].
Because our Prop1-cre; β-catGOF mutant pituitaries contain large foci which
resemble those of previous gain-of-function β-CATENIN models that have been shown
to correlate with human ACP tumors, we wanted to determine whether these high βCATENIN cell clusters possess similar features. We know that ACP tumors have a low
mitotic index, so we used Ki67 and CCND2 as proliferative markers in the Prop1-cre; β-
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catGOF mutant pituitaries (14). Ki67 is primarily restricted to the epithelial regions
outside the high β-CATENIN cell clusters, demonstrating that these cells are not actively
cycling. CCND2 is also expressed in actively cycling cells and is a target of canonical WNT
signaling (63). In large, high β-CATENIN cell clusters, CCND2 expression is significantly
reduced, confirming that these epithelial regions are not actively cycling. This decreased
expression of CCND2 in the large clusters of cells with high β-CATENIN expression is
contrary to the expected stimulation of CCND2 by canonical WNT signaling. However,
CCND2 is expressed at higher levels in smaller cell clusters with high β-CATENIN
expression, which is consistent with its role as a target of canonical WNT signaling.
These context-dependent results indicate that using CCND2 as a readout of canonical
WNT signaling in ACP tumors should be done with caution.
An intriguing observation from our study is that in wild-type embryos, β-catenin
transcription is reduced in the cells that undergo an EPT, whereas β-CATENIN protein is
still present at the cell membrane [Fig. 4.1I]. Increased levels of β-CATENIN generated
from the gain-of-function allele both inhibit EPT and shift pituitary progenitors away
from a pituitary identity. Together, these results suggest that the amount of β-CATENIN
protein in pituitary progenitors must be tightly regulated to ensure proper formation of
the pituitary anterior lobe. Decreased β-catenin transcription during EPT may provide a
regulatory mechanism for ensuring the appropriate levels of β-CATENIN protein to
provide junction stability and transcriptional regulation of the POU1F1 lineage, without
preventing EPT or promoting an oral ectoderm identity.
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The Hesx1-cre; β-catGOF and Sox2creERT2; β-catGOF mouse models, combined with
the molecular characterization of human ACP, have determined that congenital and
adult-onset ACP are caused by gain-of-function mutations in β-catenin that occur in
pituitary progenitors during embryogenesis or in adult pituitary stem cells, respectively
(56). These ACP tumors are formed in a paracrine manner, wherein a cell cluster with an
activating mutation in β-catenin signals to adjacent cells, which then proliferate and
expand to form the mass of the tumor (43). Thus, the generation of ACP relies on a cell
cluster with high β-CATENIN expression interacting with the normal anterior lobe cells
that surround it via paracrine signals. Our mouse model, Prop1-cre; β-catGOF/+, differs
from these other mouse models in that a normal pituitary anterior lobe is never formed
and the dysmorphic tissue that remains consists of periluminal epithelium with high βCATENIN expression. The earlier onset of the Hesx1-cre vs. the Prop1-cre likely causes
the difference in phenotypes. Perhaps early pituitary progenitors, which express HESX1,
can inhibit transcription from the β-catenin locus, which prevents the accumulation of
activated β-CATENIN in some cells, allowing for anterior lobe formation. Children with
activating mutations in β-catenin that mimic the onset of the Prop1-cre; β-catGOF would
present with a complete pituitary hormone deficiency at birth. The morphology of the
pituitary gland would likely resemble the initially enlarged pituitary gland of Prop1-/CPHD patients, where the pituitary progenitors fail to undergo EPT and thus do not form
an anterior lobe (31,86).
Our study highlights the importance of canonical WNT signaling through
precisely regulated levels of β-CATENIN in pituitary organogenesis. β-CATENIN is vital for
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the initial formation of pituitary progenitors and for promoting the POU1F1 lineage, but
it must also be carefully regulated in order to ensure the progression of pituitary
progenitors through EPT. Additionally, our results support previous studies by providing
further evidence towards the idea that pituitary progenitors can undergo a cell fate
switch so as to maintain balance when one cell specification pathway is inhibited. In
order to confirm this hypothesis, future studies will need to determine how the process
of cell specification is regulated in the pituitary gland and how interfering with this
process affects the regulation of pituitary progenitors. This study also provides a new
model of ACP that exhibits a different morphology compared to previous models, one in
which pituitary progenitors cannot undergo EPT or form an anterior lobe and thus do
not express markers of terminal differentiation. The molecular characterization of this
new model could be very useful in the diagnosis of patients which have activating
mutations in β-catenin but which do not exhibit the same pituitary morphology and
secondary characteristics of previously identified cases of ACP. Together, the results of
this study show that pituitary progenitors are highly sensitive to external regulation
prior to the point in which they commit to a specific cell fate, and that interfering with
these regulatory pathways prior to this key point in pituitary development can
drastically alter pituitary morphology and differentiation.
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Figure 5.1 Regulation of pituitary progenitor differentiation by β-CATENIN.
[A] Pituitary organogenesis in wild-type mice. [B] The effect on pituitary organogenesis
when β-CATENIN expression is down-regulated via cre recombination of the β-catenin
locus at e11.5 under the influence of the Prop1-cre. Red arrows in [B] indicate the downregulation of β-CATENIN and POU1F1 while green arrows indicate the up-regulation of
SF1 and TBX19. [C] The effect on pituitary organogenesis when constitutively activated
β-CATENIN is generated in Rathke’s pouch at e11.5 under the influence of the Prop1-cre.
The green arrow in [C] indicates that β-CATENIN is stimulated and the red X’s indicate
the loss of the three cell lineage markers POU1F1, SF1, and TBX19. The large curved
arrow in [C] represents the proposed reversion of cells in high β-CATENIN cell clusters to
a more oral ectoderm-like state.
65

REFERENCES
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.

Treier, M. et al. Multistep signaling requirements for pituitary organogenesis in
vivo. Genes Dev. 12, 1691–1704 (1998).
Li, S. et al. Dwarf locus mutants lacking three pituitary cell types result from
mutations in the POU-domain gene pit-1. Nature 347, 528–533 (1990).
Lamolet, B. et al. A pituitary cell-restricted T box factor, Tpit, activates POMC
transcription in cooperation with Pitx homeoproteins. Cell 104, 849–859 (2001).
Ingraham, H. A. et al. The nuclear receptor steroidogenic factor 1 acts at multiple
levels of the reproductive axis. Genes Dev. 8, 2302–2312 (1994).
Davis, S. W. et al. Pituitary gland development and disease: from stem cell to
hormone production. Curr. Top. Dev. Biol. 106, 1–47 (2013).
Sheng, H. Z. et al. Specification of Pituitary Cell Lineages by the LIM Homeobox
Gene Lhx3. Science (80-. ). 272, 1004–1007 (1996).
Andoniadou, C. L. et al. Lack of the murine homeobox gene Hesx1 leads to a
posterior transformation of the anterior forebrain. Development 134, 1499–1508
(2007).
Sornson, M. W. et al. Pituitary lineage determination by the Prophet of Pit-1
homeodomain factor defective in Ames dwarfism. Nature 384, 327–333 (1996).
Davis, S. W., Keisler, J. L., Pérez-Millán, M. I., Schade, V. & Camper, S. A. All
hormone-producing cell types of the pituitary intermediate and anterior lobes
derive from prop1-expressing progenitors. Endocrinology 157, 1385–1396 (2016).
Garcia-Lavandeira, M. et al. A GFRa2/Prop1/Stem (GPS) cell niche in the pituitary.
PLoS One 4, (2009).
De Rienzo, F. et al. Frequency of genetic defects in combined pituitary hormone
deficiency: A systematic review and analysis of a multicentre Italian cohort. Clin.
Endocrinol. (Oxf). 83, 849–860 (2015).
Capatina, C. & Wass, J. A. H. Acromegaly. J. Endocrinol. 226, T141–T160 (2015).
Sekine, S. et al. Expression of enamel proteins and LEF1 in adamantinomatous
craniopharyngioma: Evidence for its odontogenic epithelial differentiation.
Histopathology 45, 573–579 (2004).
Raghavan, R. et al. Proliferative Activity in Clinicopathological Correlations in
Adults and Children. Surg. Neurol. 54, 241–248 (2000).
Olson, L. E. et al. Homeodomain-Mediated β-Catenin-Dependent Switching
Events Dictate Cell-Lineage Determination. Cell 125, 593–605 (2006).
Gaston-Massuet, C. et al. Increased Wingless (Wnt) signaling in pituitary
progenitor/stem cells gives rise to pituitary tumors in mice and humans. Proc.
Natl. Acad. Sci. 108, 11482–11487 (2011).

66

17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.

29.
30.
31.
32.
33.

Osmundsen, A. M., Keisler, J. L., Mark Taketo, M. & Davis, S. W. Canonical WNT
signaling regulates the pituitary organizer and pituitary gland formation.
Endocrinology 158, 3339–3353 (2017).
Takuma, N. et al. Formation of Rathke’s pouch requires dual induction from the
diencephalon. Development 125, 4835–4840 (1998).
Ericson, J., Norlin, S., Jessell, T. & Edlund, T. Integrated FGF and BMP signaling
controls the progression of progenitor cell differentiation and the emergence of
pattern in the embryonic anterior pituitary. Development 125, 1005–1015 (1998).
Brinkmeier, M. L., Potok, M. A., Davis, S. W. & Camper, S. A. TCF4 deficiency
expands ventral diencephalon signaling and increases induction of pituitary
progenitors. Dev. Biol. 311, 396–407 (2007).
Potok, M. A. et al. WNT signaling affects gene expression in the ventral
diencephalon and pituitary gland growth. Dev. Dyn. 237, 1006–1020 (2008).
Davis, S. W. & Camper, S. A. Noggin regulates Bmp4 activity during pituitary
induction. Dev. Biol. 305, 145–160 (2007).
Treier, M. et al. Hedgehog signaling is required for pituitary gland development.
Development 128, 377–86 (2001).
Charles, M. A. et al. PITX Genes Are Required for Cell Survival and Lhx3 Activation.
Mol. Endocrinol. 19, 1893–1903 (2005).
Sheng, H. Z. et al. Multistep control of pituitary organogenesis. Science (80-. ).
278, 1809–1812 (1997).
Takagi, M. et al. A novel mutation in HESX1 causes combined pituitary hormone
deficiency without septo optic dysplasia phenotypes. Endocr. J. 63, 405–10
(2016).
Davis, S. W., Mortensen, A. H. & Camper, S. A. Birthdating studies reshape models
for pituitary gland cell specification. Dev. Biol. 352, 215–227 (2011).
Bilodeau, S., Roussel-Gervais, A. & Drouin, J. Distinct Developmental Roles of Cell
Cycle Inhibitors p57Kip2 and p27Kip1 Distinguish Pituitary Progenitor Cell Cycle
Exit from Cell Cycle Reentry of Differentiated Cells. Mol. Cell. Biol. 29, 1895–1908
(2009).
Fauquier, T., Rizzoti, K., Dattani, M., Lovell-Badge, R. & Robinson, I. C. A. F. SOX2expressing progenitor cells generate all of the major cell types in the adult mouse
pituitary gland. Proc. Natl. Acad. Sci. 105, 2907–2912 (2008).
Perez Millan, M. I., Brinkmeier, M. L., Mortensen, A. H. & Camper, S. A. PROP1
triggers epithelial-mesenchymal transition-like process in pituitary stem cells.
Elife 5, 1–24 (2016).
Ward, R. D. et al. Role of PROP1 in Pituitary Gland Growth. Mol. Endocrinol. 19,
698–710 (2005).
Zhu, X. et al. Sustained Notch signaling in progenitors is required for sequential
emergence of distinct cell lineages during organogenesis. Genes Dev. 20, 2739–
2753 (2006).
Gage, P. J., Roller, M. L., Saunders, T. L., Scarlett, L. M. & Camper, S. A. Anterior
pituitary cells defective in the cell autonomous factor, df, undergo cell lineage
specification but not expansion. Development 122, 151–160 (1996).
67

34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.

Böttner, A. et al. PROP1 mutations cause progressive deterioration of anterior
pituitary function including adrenal insufficiency: A longitudinal analysis. J. Clin.
Endocrinol. Metab. 89, 5256–5265 (2004).
Pulichino, A. M. et al. Tpit determines alternate fates during pituitary cell
differentiation. Genes Dev. 17, 738–747 (2003).
Lamolet, B. et al. Tpit-Independent Function of NeuroD1(BETA2) in Pituitary
Corticotroph Differentiation. Mol. Endocrinol. 18, 995–1003 (2004).
Raetzman, L. T., Cai, J. X. & Camper, S. A. Hes1 is required for pituitary growth and
melanotrope specification. Dev. Biol. 304, 455–466 (2007).
Zhao, L. et al. Steroidogenic factor 1 (SF1) is essential for pituitary gonadotrope
function. Development 128, 147–154 (2001).
Kendall, S. K., Samuelson, L. C., Saunders, T. L., Wood, R. I. & Camper, S. A.
Targeted disruption of the pituitary glycoprotein hormone α-subunit produces
hypogonadal and hypothyroid mice. Genes Dev. 9, 2007–2019 (1995).
Featherstone, K. et al. Pulsatile patterns of pituitary hormone gene expression
change during development. J. Cell Sci. 124, 3484–3491 (2011).
Gonzalez, D. M. & Medici, D. Signaling mechanisms of the epithelial-mesenchymal
transition. Sci. Signal 7, re8 (2014).
Mollard, P., Hodson, D. J., Lafont, C., Rizzoti, K. & Drouin, J. A tridimensional view
of pituitary development and function. Trends Endocrinol. Metab. 23, 261–269
(2012).
Andoniadou, C. L. et al. Sox2+stem/progenitor cells in the adult mouse pituitary
support organ homeostasis and have tumor-inducing potential. Cell Stem Cell 13,
433–445 (2013).
Vankelecom, H. Pituitary stem /progenitor cells: Embryonic players in the adult
gland? Eur. J. Neurosci. 32, 2063–2081 (2010).
Regal, M., Páramo, C., Sierra, J. M. & Garci-Mayor, R. V. Prevalence and incidence
of hypopituitarism in an adult Caucasian population in northwestern Spain. Clin.
Endocrinol. (Oxf). 55, 735–740 (2001).
Alatzoglou, K. S. & Dattani, M. T. Genetic forms of hypopituitarism and their
manifestation in the neonatal period. Early Hum. Dev. 85, 705–712 (2009).
Davis, S. W. et al. Molecular mechanisms of pituitary organogenesis: In search of
novel regulatory genes. Mol. Cell. Endocrinol. 323, 4–19 (2010).
Schneider, H. J., Aimaretti, G., Kreitschmann-Andermahr, I., Stalla, G. K. & Ghigo,
E. Hypopituitarism. Lancet 369, 1461–1470 (2007).
Asa, S. L. & Tannenbaum, G. S. Cell-cell communication in the pituitary:
orchestrator of pulsatile growth hormone secretion? Trends Endocrinol. Metab.
17, 299–300 (2006).
Tomlinson, J. W. et al. Association between premature mortality and
hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet
(London, England) 357, 425–31 (2001).
Gupta, S. et al. Craniopharyngioma: a roadmap for scientific translation.
Neurosurg. Focus 44, 1–8 (2018).

68

52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.

Andoniadou, C. L. et al. Identification of novel pathways involved in the
pathogenesis of human adamantinomatous craniopharyngioma. Acta
Neuropathol. 124, 259–271 (2012).
Nakayama, M., Tabuchi, K., Nakamura, Y. & Hara, A. Basal Cell Carcinoma of the
Head and Neck. J. Skin Cancer 2011, 1–9 (2011).
Chan, E. F., Gat, U., McNiff, J. M. & Fuchs, E. A common human skin tumour is
caused by activating mutations in beta-catenin. Nat. Genet. 21, 410–413 (1999).
Gleeson, H., Amin, R. & Maghnie, M. ‘Do no harm’: Management of
craniopharyngioma. Eur. J. Endocrinol. 159, 95–99 (2008).
Apps, J. R. & Martinez-Barbera, J. P. Molecular pathology of adamantinomatous
craniopharyngioma: review and opportunities for practice. Neurosurg. Focus 41,
E4 (2016).
Logan, C. Y. & Nusse, R. the Wnt Signaling Pathway in Development and Disease.
Annu. Rev. Cell Dev. Biol. 20, 781–810 (2004).
Grumolato, L. et al. Canonical and noncanonical wnts use a common mechanism
to activate completely unrelated coreceptors. Genes Dev. 24, 2517–2530 (2010).
van Amerongen, R. Alternative Wnt pathways and receptors. Cold Spring Harb.
Perspect. Biol. 4, (2012).
Amerongen, V., Fuerer, C., Mizutani, M. & Nusse, R. Wnt5a can both activate and
repress Wnt / b -catenin signaling during mouse embryonic development. Dev.
Biol. 369, 101–114 (2012).
Movérare-Skrtic, S. et al. Osteoblast-derived WNT16 represses osteoclastogenesis
and prevents cortical bone fragility fractures. Nat. Med. 20, 1279–1288 (2014).
Filali, M., Cheng, N., Abbott, D., Leontiev, V. & Engelhardt, J. F. Wnt-3A/β-catenin
signaling induces transcription from the LEF-1 promoter. J. Biol. Chem. 277,
33398–33410 (2002).
Kioussi, C. et al. Identification of a Wnt/Dvl/β-catenin → Pitx2 pathway mediating
cell-type-specific proliferation during development. Cell 111, 673–685 (2002).
Baek, S. H. et al. Regulated subset of G1 growth-control genes in response to
derepression by the Wnt pathway. Proc. Natl. Acad. Sci. 100, 3245–3250 (2003).
Rodda, S. J. & McMahon, A. P. Distinct roles for Hedgehog and canonical Wnt
signaling in specification, differentiation and maintenance of osteoblast
progenitors. Development 133, 3231–3244 (2006).
Polesskaya, A., Seale, P. & Rudnicki, M. A. Wnt signaling induces the myogenic
specification of resident CD45+ adult stem cells during muscle regeneration. Cell
113, 841–852 (2003).
Douglas, K. R. et al. Identification of members of the Wnt signaling pathway in the
embryonic pituitary gland. Mamm. Genome 12, 843–851 (2001).
Huelsken, J. et al. Requirement for beta-catenin in anterior-posterior axis
formation in mice. J. Cell Biol. 148, 567–578 (2000).
Bingham, N. C., Verma-Kurvari, S., Parada, L. F. & Parker, K. L. Development of a
Steirodogenic Factor 1/Cre Transgenic Mouse Line. Genesis 44, 419–424 (2006).
Harada, N. et al. Intestinal polyposis in mice with a dominant stable mutation of
the β-catenin gene. EMBO J. 18, 5931–5942 (1999).
69

71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.

83.
84.
85.
86.

Brault, V. et al. Inactivation of the beta-catenin gene by Wnt1-Cre-mediated
deletion results in dramatic brain malformation and failure of craniofacial
development. Development 128, 1253–1264 (2001).
Bjelobaba, I., Janjic, M. M., Kucka, M. & Stojilkovic, S. S. Cell Type-Specific Sexual
Dimorphism in Rat Pituitary Gene Expression During Maturation. Biol. Reprod. 93,
1–9 (2015).
Hogan, B., Beddington, R., Costantini, F. & Lacey, E. Manipulating the mouse
embryo: a laboratory manual. (Cold Spring Harbor Laboratory Press, 1994).
Gergics, P., Brinkmeier, M. L. & Camper, S. A. Lhx4 Deficiency: Increased CyclinDependent Kinase Inhibitor Expression and Pituitary Hypoplasia. Mol. Endocrinol.
29, 597–612 (2015).
Raetzman, L. T. et al. Developmental regulation of Notch signaling genes in the
embryonic pituitary: Prop1 deficiency affects Notch2 expression. Dev. Biol. 265,
329–340 (2004).
Voss, J. W., Wilson, L., Rhodes, S. J. & Rosenfeld, M. G. An alternative Pit-1 RNA
splicing product reveals modular binding and nonmodular transcriptional
activities of the POU-specific domain. Mol. Endocrinol. 7, 1551–1560 (1993).
Paek, H., Hwang, J. Y., Zukin, R. S. & Hébert, J. M. β-catenin-dependent FGF
signaling sustains cell survival in the anterior embryonic head by countering
Smad4. Dev. Cell 20, 689–699 (2011).
Chaturvedi, K. & Sarkar, D. K. Isolation and characterization of rat pituitary
endothelial cells. Neuroendocrinology 83, 387–393 (2006).
Lodge, E. J., Russell, J. P., Patist, A. L., Francis-West, P. & Andoniadou, C. L.
Expression analysis of the Hippo cascade indicates a role in pituitary stem cell
development. Front. Physiol. 7, 1–11 (2016).
Cheung, L. Y. M., Davis, S. W., Brinkmeier, M. L., Camper, S. A. & Pérez-Millán, M.
I. Regulation of pituitary stem cells by epithelial to mesenchymal transition events
and signaling pathways. Mol. Cell. Endocrinol. 445, 14–26 (2017).
Muzumdar, M. D., Tasic, B., Miyamichi, K., Li, L. & Luo, L. A Global DoubleFluorescent Cre Reporter Mouse. Genesis 45, 593–605 (2007).
Zhang, Z., Florez, S., Gutierrez-Hartmann, A., Martin, J. F. & Amendt, B. A.
MicroRNAs regulate pituitary development, and microRNA 26b specifically targets
lymphoid enhancer factor 1 (Lef-1), which modulates pituitary transcription factor
1 (Pit-1) expression. J. Biol. Chem. 285, 34718–34728 (2010).
Suga, H. et al. Self-formation of functional adenohypophysis in three-dimensional
culture. Nature 480, 57–62 (2011).
Ozone, C. et al. Functional anterior pituitary generated in self-organizing culture
of human embryonic stem cells. Nat. Commun. 7, 1–10 (2016).
Zimmer, B. et al. Derivation of diverse hormone-releasing pituitary cells from
human pluripotent stem cells. Stem Cell Reports 6, 858–872 (2016).
Nascif, S. O., Vieira, T. C., Ramos-Dias, J. C., Lengyel, A. M. J. & Abucham, J.
Waxing and waning of a pituitary mass in a young woman with combined
pituitary hormone deficiency (CPHD) due to a PROP-1 mutation. Pituitary 9, 47–
52 (2006).
70

APPENDIX A: PERMISSION TO REPRINT
Endocrinology by HighWire Press; Reproduced with permission from the
Endocrine Society in the format of Thesis/Dissertation via the Copyright Clearance
Center.

71

72

73

74

75

76

